

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/019098

INTERNATIONAL APPLICATION NO.  
PCT/IB99/01166INTERNATIONAL FILING DATE  
22 June 1999PRIORITY DATE CLAIMED  
NONE

## TITLE OF INVENTION

## IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

## APPLICANT(S) FOR DO/EO/US

HAFEN, Ernst

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4.  The US has been elected by the expiration of 19 months from the priority date (Article 31).
5.  A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a.  is attached hereto (required only if not communicated by the International Bureau).
  - b.  has been communicated by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is attached hereto.
  - b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a.  are attached hereto (required only if not communicated by the International Bureau).
  - b.  have been communicated by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.  An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.  A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.  A copy of the International Search Report (PCT/ISA/210).

## Items 13 to 20 below concern document(s) or information included:

13.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.  A **FIRST** preliminary amendment.
16.  A **SECOND** or **SUBSEQUENT** preliminary amendment.
17.  A substitute specification.
18.  A change of power of attorney and/or address letter.
19.  A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20.  A second copy of the published international application under 35 U.S.C. 154(d)(4).
21.  A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22.  Certificate of Mailing by Express Mail
23.  Other items or information:

Corrected International Preliminary Examination Report; Sequence Listing in paper form; Sequence Statement pursuant to 37 C.F.R. 1.821-1.825; and Return receipt post card.

U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR 1.137(a))	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
107019098	PCT/IB99/01166	27656/38053


24. The following fees are submitted:	CALCULATIONS PTO USE ONLY		
<b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b>			
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1040.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00			
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b> <input type="text" value="890.00"/>			
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).		<input type="checkbox"/> 20	<input type="checkbox"/> 30
		\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	34 - 20 =	14	x \$18.00 \$252.00
Independent claims	3 - 3 =	0	x \$84.00 \$0.00
Multiple Dependent Claims (check if applicable).		<input type="checkbox"/>	
		\$0.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b> <input type="text" value="1,142.00"/>			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.			
<b>SUBTOTAL =</b> <input type="text" value="1,142.00"/>			
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).		<input type="checkbox"/> 20	<input type="checkbox"/> 30
		+ \$0.00	
<b>TOTAL NATIONAL FEE =</b> <input type="text" value="1,142.00"/>			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).		<input type="checkbox"/>	
		\$0.00	
<b>TOTAL FEES ENCLOSED =</b> <input type="text" value="1,142.00"/>			
		Amount to be: refunded	\$
		charged	\$

- A check in the amount of \$1,142.00 to cover the above fees is enclosed.
- Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-2855 A duplicate copy of this sheet is enclosed.
- Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jeffrey S. Sharp  
Customer No.: 04743  
MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606  
United States of America

  
SIGNATURE

Jeffrey S. Sharp

NAME

31,879

REGISTRATION NUMBER

20 December 2001

DATE


10/019098  
531 Rec'd PCT/FI 20 DEC 2001

PATENT  
Attorney Docket No.: 27656/38053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HAFEN, Ernst ) I hereby certify that this paper is being de-  
U.S. National Phase of PCT/IB99/01166 filed ) posited with the United States Postal Ser-  
22 June 1999 ) vice on **December 20, 2001**, in an envelope  
Filed: Herewith ) addressed to the Commissioner for Patents,  
For: IN VIVO INSECT MODEL SYSTEM ) Washington, D.C. 20231 utilizing the "Ex-  
FOR TYPE-2 DIABETES ) press Mail Post Office to Addressee" ser-  
Group Art Unit: Unassigned ) vice of the United States Postal Service un-  
Examiner: Unassigned ) der Mailing Label No. **EK 657 819 788 US.**  
Attorney Docket No. 27656/35053 )  
)  
)  
)  
)  
)  
)

December 20, 2001

  
Richard Zimmermann

STATEMENT UNDER 37 C.F.R. §§1.821(f)

BOX PCT  
Commissioner for Patents  
Washington, DC 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with 37 C.F.R. §§1.821 and 1.825, are the same.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

By

  
Jeffrey S. Sharp  
Registration No. 31,879  
Attorney for Applicants

December 20, 2001

SEQUENCE LISTING

<110> HAFEN, Ernst

<120> In vivo model system for type-2 diabetes

<130> 27656/38053

<140> To be determined  
<141> To be determined

<150> PCT/IB99/01166  
<151> 1999-06-22

<160> 4

<170> PatentIn Ver. 2.1

<210> 1  
<211> 2907  
<212> DNA  
<213> Drosophila melanogaster

<400> 1  
atggcatcaa tatcgatga cggcatggcg ctgagtggct acctaagaa gctgaagacc 60  
atgaagaaga agttctttgt gctgtacgag gagacgagca ctccggcagc ccggctggag 120  
tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180  
aagaattgct tcaacatcaa tcgccgttg gacaccaagc atagatttgt cattgtgctc 240  
tcctccagag acgggtggatt cggcatcggt ctgcagaacg aaaaatgattt acgcaaatgg 300  
ttggacaaac tactagttct acaaaggaac atagccaatt cgaatggAAC agcgcactca 360  
ccttatgacc acgtttggca agttgtcatt caaaaagaagg gtatTTcgga gaaagttgga 420  
atcaccggaa cttaccactg ttgccttact tcaaaaatccc tgacattcgt gtgcattgga 480  
ccggagaaga cgcccaatgg cgaggatcg gttgcgagca ttgaaatact tttgaccacg 540  
atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggaact tggccgccaa 600  
agtgtcttgg gatctggatg tctgtggatg gagacggata acgcagctat tgctactaat 660  
atgcacaaaca cgatactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720  
aacgtttatc agaatacgacc tgacttaagt cacgagccca tgagaaagcg atcgctgtct 780  
gcaaacgaag catcgaaGCC gataaacgt aatgtcatac aaaaatagtca aaactctctc 840  
gaattgcgca gctgcagttc gccccataac tatggttcg gcagagagag atgcgatagc 900  
ttaccaacca gaaatggAAC cctaagcgag tccagcaatc aaacgtactt tggttccaac 960  
catggactgc gatccaatac tatactggc atccgtccgc actcaaccaa caagcatagt 1020  
aatagtccaa cgttcaccat gccaataga tgctcagaat ccgaagagtc atcaattagt 1080  
gtcgatgaat ccgacgacaa cggcagttt agccactaca gattaaacac gcggtcatct 1140

gagacggcaa ttcctgagga aaacattgat gactttgcca gtgcggaaatt atttgc 1200  
gtcaccgaac aaaatgtaa tgacgaaaac tacataccga tgaatccagt caatcctacc 1260  
gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaaagatgc ttcgctgcat 1320  
ttcaacttgc cgagcacgc gtcggaaaag cttgctaagg attttgc 1380  
aaccaatgtc gtcgccat tcgcccatt tcgataggca acaagggtga gcatttaaag 1440  
ttaataagc gcctgggaca cttgaatgt acgggacaga atccgaatcg cgtgcgagcc 1500  
tactcggttgc gctccaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcg 1560  
gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620  
accagctatg gcagcagtgc caatcgacaa aagaagtcca caagtgc 1680  
ctgaagaacc agataaaactc cgaccgaatg agtgcattaa tggaaattga ttttcacaa 1740  
gcaaccaatt tggaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800  
aacgtgttcc caaaagcccc gcgaacggat agtccagcc taactctgca cgccacaagt 1860  
caaaaggaca ttttcaatgg caccaacta aataacactg cgatcacatc cgaggatgg 1920  
tacctcgaga tgaagccagt cggtaatggc tacactccca gttcgaatttgc 1980  
aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040  
gcaccagtgc acgatttaaa caaaattgc acatacaata tatccgctga gaaatggaga 2100  
gaacagcccc gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacacctt 2160  
agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttcagcaa 2220  
caaattgatt gcgagaaagt gtgcgcgcag agcagcgata agctaaataa tcatctggcc 2280  
gacaagatttgc tgcgaaacaa caatttggat ataggcgggc atgagggaaa gaagttgg 2340  
cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400  
tttaacgaag ccggctacaa aattctgca attaaaagcg acagctcact catctcatcg 2460  
aagctataacc aaaagggtat acacaaggat aacttggagc gttcgcagag acttacagag 2520  
agtgtgaata cgattcccgtaatgccacc gcccacgcgg tgagcagcag ctcactcacc 2580  
aaattcaata taaattcagc aaagccagcc gcccgcgcg attcgcgtac cactggcaca 2640  
gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaagggtcg 2700  
tcgtctcgca tatcccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760  
ggccaaaatc cagctaaata cctgaagaga ggatcagcgc aatcgccgc ggtgtccgca 2820  
tgcccggagg atggaataac ctatgcgaaa atgcactttg accaatccga ctcctttcc 2880  
tcctcatcgaa acatatttaa tacgtaa 2907

<210> 2  
<211> 2907  
<212> DNA  
<213> Drosophila melanogaster

<220>  
<221> CDS  
<222> (1)..(2907)

<400> 2  
atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag 48  
Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys  
1 5 10 15

aag ctg aag acc atg aag aag ttc ttt gtg ctg tac gag gag acg 96  
Lys Leu Lys Thr Met Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
20 25 30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc 144  
Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
35 40 45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc 192  
Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe  
50 55 60

aac atc aat cgc cgt ttg gac acc aag cat aga ttt gtc att gtg ctc 240  
Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu  
65 70 75 80

tcc tcc aga gac ggt gga ttc ggc atc gtt ctc gag aac gaa aat gat 288  
Ser Ser Arg Asp Gly Gly Ile Val Leu Glu Asn Glu Asn Asp  
85 90 95

tta cgc aaa tgg ttg gac aaa cta cta gtt cta caa agg aac ata gcc 336  
Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala  
100 105 110

aat tcg aat gga aca gcg cac tca cct tat gac cac gtt tgg caa gtt 384  
Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val  
115 120 125

gtc att caa aag aag ggt att tcg gag aaa gtt gga atc acc gga acc 432  
Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr  
130 135 140

tac cac tgt tgc ctt act tca aaa tcc ctg aca ttc gtg tgc att gga 480  
Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly  
145 150 155 160

ccg gag aag acg ccc aat ggc gag gat cgc gtt gcg agc att gaa ata 528  
Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile  
165 170 175

ctt ttg acc acg atc agg cga tgc ggt cat gca tcc cca caa tgt ata 576  
Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile  
180 185 190

ttc tac gtg gaa ctt ggc cgc caa agt gtc ttg gga tct ggt gat ctg 624  
Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu  
195 200 205

tgg atg gag acg gat aac gca gct att gct act aat atg cac aac acg Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr 210 215 220	672
ata ctg agc gct atg tca gcc aaa aca gag tcg aac acg aat tta ata Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile 225 230 235 240	720
aac gtt tat cag aat aga cct gac tta agt cac gag ccc atg aga aag Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys 245 250 255	768
cga tcg tcg tct gca aac gaa gca tcg aag ccg ata aac gta aat gtc Arg Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val 260 265 270	816
ata caa aat agt caa aac tct ctc gaa ttg cgc agc tgc agt tcg ccc Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro 275 280 285	864
cat aac tat ggt ttc ggc aga gag aga tgc gat agc tta cca acc aga His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg 290 295 300	912
aat gga acc cta agc gag tcc agc aat caa acg tac ttt ggt tcc aac Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn 305 310 315 320	960
cat gga ctg cga tcc aat act ata tct ggc atc cgt ccg cac tca acc His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr 325 330 335	1008
aac aag cat agt aat agt cca acg ttc acc atg cca tta aga tgc tca Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser 340 345 350	1056
gaa tcc gaa gag tca tca att agt gtc gat gaa tcc gac gac aac ggc Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly 355 360 365	1104
agt ttt agc cac tac aga tta aac acg cgg tca tct gag acg gca att Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile 370 375 380	1152
cct gag gaa aac att gat gac ttt gcc agt gcg gaa tta ttt agc aaa Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys 385 390 395 400	1200
gtc acc gaa caa aat gta agt gac gaa aac tac ata ccg atg aat cca Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro 405 410 415	1248
gtc aat cct acc gat gct atc cat gaa aag gag aag gct gat atg cag Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln 420 425 430	1296
aga ttg gaa gat gct tcg ctg cat ttc aac ttt ccg gag cac gcg tcg Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser 435 440 445	1344
gaa aag ctt gct aag gat ttt gat ctg gac tct gat aac caa tgc tgt Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys 450 455 460	1392

cgt ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag	1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys	
465 470 475 480	
ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat	1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn	
485 490 495	
cgc gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc	1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys	
500 505 510	
gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca	1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr	
515 520 525	
gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc	1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly	
530 535 540	
agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt	1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser	
545 550 555 560	
ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att	1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile	
565 570 575	
gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat	1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gin Lys Phe Ile Lys Asn	
580 585 590	
aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga	1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg	
595 600 605	
acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att	1872
Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile	
610 615 620	
ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt	1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly	
625 630 635 640	
tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat	1968
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn	
645 650 655	
tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca	2016
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr	
660 665 670	
gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa	2064
Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys	
675 680 685	
att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc	2112
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser	
690 695 700	
aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt	2160
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe	
705 710 715 720	

agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt		2208	
Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val			
725	730	735	
cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc		2256	
His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser			
740	745	750	
gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat		2304	
Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn			
755	760	765	
ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc		2352	
Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser			
770	775	780	
agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa		2400	
Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys			
785	790	795	800
ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca		2448	
Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser			
805	810	815	
ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg		2496	
Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu			
820	825	830	
gag cgt tcg cag aga ctt aca gag agt gtg aat acg att ccc gat aat		2544	
Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn			
835	840	845	
gcc acc gcc acc gcg gtg agc agc tca ctc acc aaa ttc aat ata		2592	
Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile			
850	855	860	
aat tca gca aag cca gcc gcc gat tcg cgt agc act ggc aca		2640	
Asn Ser Ala Lys Pro Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr			
865	870	875	880
gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc		2688	
Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe			
885	890	895	
ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc		2736	
Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala			
900	905	910	
agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg		2784	
Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu			
915	920	925	
aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat		2832	
Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp			
930	935	940	
ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc		2880	
Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser			
945	950	955	960
tcc tca tcg aac ata ttt aat acg taa		2907	
Ser Ser Ser Asn Ile Phe Asn Thr			
965			

<210> 3  
 <211> 968  
 <212> PRT  
 <213> Drosophila melanogaster

<400> 3  
 Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys  
 1 5 10 15

Lys Leu Lys Thr Met Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
 20 25 30

Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
 35 40 45

Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe  
 50 55 60

Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu  
 65 70 75 80

Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp  
 85 90 95

Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala  
 100 105 110

Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val  
 115 120 125

Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr  
 130 135 140

Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly  
 145 150 155 160

Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile  
 165 170 175

Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile  
 180 185 190

Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu  
 195 200 205

Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr  
 210 215 220

Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile  
 225 230 235 240

Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys  
 245 250 255

Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val  
 260 265 270

Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro  
 275 280 285

His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg  
 290 295 300

Asn	Gly	Thr	Leu	Ser	Glu	Ser	Ser	Asn	Gln	Thr	Tyr	Phe	Gly	Ser	Asn
305					310					315					320
His	Gly	Leu	Arg	Ser	Asn	Thr	Ile	Ser	Gly	Ile	Arg	Pro	His	Ser	Thr
					325				330						335
Asn	Lys	His	Ser	Asn	Ser	Pro	Thr	Phe	Thr	Met	Pro	Leu	Arg	Cys	Ser
						340			345					350	
Glu	Ser	Glu	Glu	Ser	Ser	Ile	Ser	Val	Asp	Glu	Ser	Asp	Asp	Asn	Gly
						355		360				365			
Ser	Phe	Ser	His	Tyr	Arg	Leu	Asn	Thr	Arg	Ser	Ser	Glu	Thr	Ala	Ile
						370		375				380			
Pro	Glu	Glu	Asn	Ile	Asp	Asp	Phe	Ala	Ser	Ala	Glu	Leu	Phe	Ser	Lys
						385		390			395				400
Val	Thr	Glu	Gln	Asn	Val	Ser	Asp	Glu	Asn	Tyr	Ile	Pro	Met	Asn	Pro
						405			410					415	
Val	Asn	Pro	Thr	Asp	Ala	Ile	His	Glu	Lys	Glu	Lys	Ala	Asp	Met	Gln
						420		425				430			
Arg	Leu	Glu	Asp	Ala	Ser	Leu	His	Phe	Asn	Phe	Pro	Glu	His	Ala	Ser
						435		440				445			
Glu	Lys	Leu	Ala	Lys	Asp	Phe	Asp	Leu	Asp	Ser	Asp	Asn	Gln	Cys	Cys
						450		455				460			
Arg	Pro	Ile	Arg	Ala	Tyr	Ser	Ile	Gly	Asn	Lys	Val	Glu	His	Leu	Lys
						465		470			475				480
Phe	Asn	Lys	Arg	Leu	Gly	His	Leu	Asn	Asp	Thr	Gly	Gln	Asn	Pro	Asn
						485			490					495	
Arg	Val	Arg	Ala	Tyr	Ser	Val	Gly	Ser	Lys	Ser	Lys	Ile	Pro	Arg	Cys
						500			505					510	
Asp	Leu	Gln	Arg	Val	Val	Leu	Val	Glu	Asp	Asn	Lys	His	Glu	Phe	Thr
						515		520				525			
Ala	Asn	Arg	Ser	Gln	Ser	Ser	Ile	Thr	Lys	Glu	Gly	Thr	Ser	Tyr	Gly
							530	535				540			
Ser	Ser	Ala	Asn	Arg	Gln	Lys	Lys	Ser	Thr	Ser	Ala	Pro	Leu	Leu	Ser
							545		550			555			560
Leu	Lys	Asn	Gln	Ile	Asn	Ser	Asp	Arg	Met	Ser	Asp	Leu	Met	Glu	Ile
							565		570					575	
Asp	Phe	Ser	Gln	Ala	Thr	Asn	Leu	Glu	Lys	Gln	Lys	Phe	Ile	Lys	Asn
						580		585				590			
Asn	Glu	Ile	Pro	Lys	Tyr	Ile	Glu	Asn	Val	Phe	Pro	Lys	Ala	Pro	Arg
						595		600				605			
Thr	Asp	Ser	Ser	Ser	Leu	Thr	Leu	His	Ala	Thr	Ser	Gln	Lys	Asp	Ile
						610		615				620			
Phe	Asn	Gly	Thr	Lys	Leu	Asn	Asn	Thr	Ala	Ile	Thr	Ser	Glu	Asp	Gly
						625		630				635			640

Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn  
645 650 655

Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr  
660 665 670

Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys  
675 680 685

Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser  
690 695 700

Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe  
705 710 715 720

Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val  
725 730 735

His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser  
740 745 750

Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn  
755 760 765

Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser  
770 775 780

Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys  
785 790 795 800

Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser  
805 810 815

Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu  
820 825 830

Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn  
835 840 845

Ala Thr Ala Thr Ala Val Ser Ser Ser Ser Leu Thr Lys Phe Asn Ile  
850 855 860

Asn Ser Ala Lys Pro Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr  
865 870 875 880

Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe  
885 890 895

Pro Ser Arg Ser Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala  
900 905 910

Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu  
915 920 925

Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp  
930 935 940

Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser  
945 950 955 960

Ser Ser Ser Asn Ile Phe Asn Thr  
965

<210> 4  
<211> 5210  
<212> DNA  
<213> Drosophila melanogaster

<400> 4  
agaacgactt tttccctcctt agtcagtcac aagaaaacta aagcttacca acaatacggc 60  
gtgtattgtt aaattattac aacaaataaa atattcaa atgtat tttttaaa aatata gtaa 120  
ccattaaaaaa ataaaatcaa tatgcgaaac tttgtat cttactcatc cttttttt 180  
gagcccgctt tcttaagtta aatcgtaaa ataccagttt aatcattca ttgtcctgat 240  
ttcaggagct aattacat ttttgtt ataaattcat aaaataaaaa tggaaatgtt 300  
taaccacata aaatatttgg gtatataaag tcgatacata cttttaaaat tttgtttcat 360  
acaagaatat ggaaagtaga taattttagt accgattaaa acatttctaa aatacaaaaaa 420  
attnnnnnat atgattaaat aaaaaactgt tatactaaat ttaaacgaaa caaacggtca 480  
ttcgataact caattagttt cgaataagcc ggcgtgtaaa tcgggttggc aactctcacc 540  
ggtagaga tcgggatggc aacttcgtat tgtttattcct atgctgcgtt aacgataaca 600  
gcaaaagtgtc atcgcaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660  
aataatacaa atgctaaatg tttttttttt ataaatgtt aacactgatt tcgatgtat 720  
cgccatcatacg ggcagctaga cgttttagt aacacatttc ccagccacat tggcgatgtt 780  
gtattatttc ccataccat gtgcgtttgtt aaatgataacc accagagtgtt gccatgtt 840  
tcgttgcgtt tacatacatg cctacggggaaaataactc gcagatacat atgtatgtaa 900  
gatgtattttag aattccacag atatatgtac atataatataat atatatataat ttatgtatgtt 960  
catctataaa acaaaatatg tacaaacata cgccgcacg tacttatgtt tttttttttt 1020  
catatataca tttttttttt ataaaatgtt catctatgtt cggttatctt aatgcaatgc 1080  
gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaattatg 1140  
aattcacaat tccacatcca attccgattt cgaattccat cgcttacat ccttacat 1200  
atacgtcgcc cccgttacatccat tttttttttt tttttttttt 1260  
tgattgcgtt ttccgatgtt cgttgcgtt gatgttgcgtt gatgttgcgtt 1320  
attgcgttgcgtt cttttttttt tttttttttt 1380  
aaatgttttgcgtt gatgttgcgtt gatgttgcgtt gatgttgcgtt 1440  
tacattatgtt cttttttttt 1500  
aacattatac atgtgttgcgtt tttttttttt 1560  
aaatatgtgtt cttttttttt 1620  
tggaaatcat ggcataata tcggatgacg gcatggcgct gatggctac ctcaagaagc 1680  
tgaagaccat gaagaagaag ttctttgtgc tttttttttt 1740

ggctggagta ctacgatacc gaaaagaagt tcctcaaag agccgagcca aaaagggtta 1800  
tctatctgaa gaattgcttc aacatcaatc gccgtttggc caccaagcat agatttgtca 1860  
ttgtgcttc ctccagagac ggtggattcg gcatcgatc cgagaacgaa aatgatttac 1920  
gcaaatgggt ggacaaacta ctatgttac aaaggaacat agccaattcg aatgaaacag 1980  
cgcaactcacc ttatggatg ccaaataaac tataactacc agttagttagtggaaac 2040  
acttcatttc actttgcaga ccacggttgg caagttgtca ttcaaaagaa gggtatttcg 2100  
gagaaaagttg gaatcaccgg aacctaccac tggtgcctta cttcaaaatc cctgacattc 2160  
gtgtgcattt gaccggagaa gacgccaat ggcgaggatc gcgttgcgag cattgaaata 2220  
cttttgcacca cgatcaggcg gttagttgtt gccagcaaaa ctgcaaggaa ttgtaaaata 2280  
atccggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340  
tggccgccaat agtgttgcgatc gatctggatc tctgtggatg gagacggata acgcagctat 2400  
tgctactaat atgcacaaca cgatactgag gtatttagct ctcattacaa ctaatccaag 2460  
atttcatgtatc catcctacaa aacgacatag atagtttaag atatctccca gttaacttta 2520  
ataattctgt gggtttttc ttccagcgatc atgtcagcca aaacagagtc gaacacgaat 2580  
ttaataaaacg tttatcagaa cagacctgac ttaagtcaacg agcccatgag aaagcgatcg 2640  
tagtctgcaaa acgaagcatc gaagccgata aacgtaaatg tcatacaaaa tagtcaaaaac 2700  
tctctcgaaat tgccgcagctg cagttcgccc cataactatg gtaaataactt caaatgtatg 2760  
tttaaacgca aaattaatca aacgcaatcg ttccaggttt cggcagagag agatgcgata 2820  
ggttaccaac cagaaatggc accctaagcg agtccagcaa tcaaacgtac ttgggttcca 2880  
accatggact gcgatccaaat actatatactg gcatccgtcc gcactcaacc aacaagcata 2940  
gtaatagtcc aacgttcacc atgcccattaa gatgctcaga atccgaagag tcataatta 3000  
gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060  
tcaaataata attatttaat aataatcacc atttcaattt ctagcacgatc gtcatctgag 3120  
acggcaatttccgatc ctgaggaaaa cattgatgac ttgcgcagtg cgaaattttagtca 3180  
accgaacaaa atggtaagcc aaacacaaaa acaattttt aacatgaaaa gtagctaata 3240  
aattggctttt gtttaactgc agtaagtgc gaaaactaca taccgatgaa tccagtcaat 3300  
cctaccgatc ctatccatga aaaggagaag gctgatgc agagattggc agatgcttcg 3360  
ctgcatttca actttccgga gcacgcgtcg gaaaagcttgcgatcattt tgatctggac 3420  
tctgataacc agttagtaca catttcgatc caactgtgcc acgtaatgca atcaatcaca 3480  
tcttggatcata gatgctgtcg tcccaattcg gcctattcgatc taggcaacaa ggttggatc 3540  
ttaaaatgttata ataagcgctt gggacacttg aatgatacgg gacagaatcc gaatcgatcg 3600  
cgagccacttccgatc caaatcgatc acccgatcgatc gcgacctgca gcgagtggatc 3660

ctcgtggagg acaataaaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720  
gaaggaacca gctatggcag cagtgc当地 cgacaaaaga agtccacaag tgctccactc 3780  
ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840  
tcacaagcaa ccaatttggaa aaagcagaag ttcatcaaga ataatgaaat tccgaaatac 3900  
attgaaaacg tgcccaaaa agccccgcga acggatagct ccagcctaac tctgcacgccc 3960  
acaagtcaaa aggacatccc caatggcacc aaactaaata acactgcgat cacatccgag 4020  
gatggttacc tcgagatgaa gccagtcggt aatggataca ctcccagttc gaattgcctg 4080  
ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgccc aatcaccgca 4140  
acagccgcac cagtgcacga tttaaacaaaa attagcacat acaatatac cgctgagaaa 4200  
tggagagaac agcccagcag aagcgaggaa aagaagtcga actcgccatt gaatgacaac 4260  
acctttggct tgaaacccac aaatgtcgag agtacaagca aaagccatga tgccattca 4320  
gcaaatcaaa ttgattccga gaaagtgtgc ggcgcagagca ggcataagct aaataatctg 4380  
ggcgcacaaga ttgtcgagaa caacaatttg gatataggcg ggcgcagagca aaagaagttg 4440  
gttcattcga taagcagcga agactacaca caaatcaagg acaaatcgaa tgatttcaca 4500  
aaatttaacg aagccggcta caaaattctg caaataaaaa ggcgcacgctc actcatctca 4560  
tcgaagctat accaaaaggg tatacacaag gataacttgg agcgccatcgca gagacttacg 4620  
gagagtgtga atacgattcc cgataatgccc accggccaccg cggtgagcag cagctccactc 4680  
accaaattca atataaattc agcaaagccca ggcgcgcgcg ccgattcgcc tagcactggc 4740  
acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800  
tcgtcgctc gcatatccca gcccggagctg cactacgcca gccttagatct tcccccattgc 4860  
agtggccaaa atccagctaa atacctgaaag agaggatcac ggcgcacgccc gcccgggttcc 4920  
gcatgcccgg aggatggaa tacctatcgaaa aaaatcgact ttgaccaatc cgactccctct 4980  
tcctccat cgaacatatt taatacgtaa agtttgaaa ttatgaccc tatccatat 5040  
atatgatttgc ttatatttgc tacatttttgc gtaaatattc tctgacaaggc aaagcttaca 5100  
attttggatg ctaataaata aatttttattt aaattataat gatccctttg gactttttt 5160  
ttttttggac taagaaatca ctactaaaga agggctttc gagggtaaa 5210

10/019098  
531 Rec'd PCT 20 DEC 2001

PATENT APPLICATION

IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Applicant: HAFEN, Ernst

U.S. National Phase of PCT/IB99/01166 filed 22  
June 1999

Filed: Herewith

For: IN VIVO INSECT MODEL SYSTEM  
FOR TYPE-2 DIABETES


Group Art Unit: Unassigned

Examiner: Unassigned

Attorney Docket No. 27656/35053

) I hereby certify that this paper is being depos-  
ited with the United States Postal Service on  
December 20, 2001, in an envelope addressed  
to the Commissioner for Patents, Washing-  
ton, D.C. 20231 utilizing the "Express Mail  
Post Office to Addressee" service of the  
United States Postal Service under Mailing  
Label No. EK 657 819 788 US.

) December 20, 2001

  
Richard Zimmermann

PRELIMINARY AMENDMENT ACCOMPANYING FILING  
OF NATIONAL STAGE APPLICATION UNDER 35 U.S.C. 371

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

AMENDMENT

Please amend claims 1, 4-5, 8-10, 12-14, 17-18, 21, 23, 25-31 as follows:

In the Claims:

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

4. [AMENDED] The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. [AMENDED] The method of claim 2 wherein the Drosophila mutant comprises one wild-type *chico* gene.

8. [AMENDED] The method of claim 2 wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

10. [AMENDED] The method of claim 2 wherein the Drosophila lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 which is a fly mutant.

26. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects and that viable offsprings with altered cell number, cell size, developmental time or lipid levels are cultivated under suitable conditions.

Please add the following claims:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.--

REMARKS


The foregoing amendments are made to change multiple dependencies. No new matter is introduced thereby and allowance of all claims 1-34 is hereby solicited.

Attached hereto as pages 6 through 9 is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned  
**“Version With Markings to Show Changes Made.”**

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By

  
Jeffrey S. Sharp, Reg. No. 31,879  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

Chicago, Illinois  
December 20, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 1, 4-5, 8-10, 12-14, 17-18, 21, 23, 25-31 have been amended as follows:

1. [AMENDED] A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, [and/or] cell size, [and/or] development time [and/] or lipid level is determined whereby alterations of the body size, [and/or] cell size, [and/or] development time [and/] or lipid level are detectable in at least part of the animal.
  
4. [AMENDED] The method of claim 2 [or 3] wherein the mutant does not comprise a wild-type *chico* gene.
  
5. [AMENDED] The method of claim 2 [or 3] wherein the Drosophila mutant comprises one wild-type *chico* gene.
  
8. [AMENDED] The method of claim 2 [anyone of claims 2 to 7] wherein the Drosophila mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.
  
10. [AMENDED] The method of claim 2 [anyone of claims 2 to 9] wherein the Drosophila lacks at least one *chico* gene.

12. [AMENDED] The method of claim 2 [anyone of claims 1 to 11] wherein the compound is a compound for the treatment of diabetes type 2.

13. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. [AMENDED] The method of claim 2 [anyone of claims 1 to 12,] wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

17. [AMENDED] The mutant of claim 15 [or 16] that does not comprise a wild-type *chico* gene.

18. [AMENDED] The mutant of claim 15 [or 16] that comprises one wild-type *chico* gene.

21. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 20] comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

23. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 22] lacking at least one *chico* gene.

25. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 24] which is a fly mutant[, in particular a *Drosophila* mutant].

26. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. [AMENDED] The mutant of claim 15 [anyone of claims 15 to 25,] wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27,] as a means in screening compounds for modulating diseases.

29. [AMENDED] Use of an insect according to claim 15 [anyone of claims 15 to 27] as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. [AMENDED] Use according to claim 22 [or 23,] characterized in that the disease is diabetes type 2.

31. [AMENDED] A method for generating a mutant insect, characterized in that adult animals[, in particular males,] are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, [and/or] cell size, [and/or] developmental time [and/or] lipid levels are cultivated under suitable conditions.

Claims 32-34 have been added as follows:

--32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.--

CLEAN VERSION OF CLAIMS AFTER AMENDMENT

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable *chico* mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size, cell size, development time or lipid level is determined whereby alterations of the body size, cell size, development time or lipid level are detectable in at least part of the animal.

2. The method of claim 1 characterized in that the viable *chico* mutant insect comprises at most one wild-type *chico* gene.

3. The method of claim 2 wherein the mutant is a *Drosophila* mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.

4. The method of claim 2 wherein the mutant does not comprise a wild-type *chico* gene.

5. The method of claim 2 wherein the *Drosophila* mutant comprises one wild-type *chico* gene.

6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).

8. The method of claim 2 wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of claim 2 wherein the *Drosophila* lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

12. The method of claim 2 wherein the compound is a compound for the treatment of diabetes type 2.

13. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the whole animal.

14. The method of claim 2 wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level is detectable in the head region only.

15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

16. The mutant of claim 15 that does not comprise as sole *chico* genes two *chico* genes.

17. The mutant of claim 15 that does not comprise a wild-type *chico* gene.

18. The mutant of claim 15 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

21. The mutant of claim 15 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of claim 15 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

25. The mutant of claim 15 which is a fly mutant.

26. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the whole body of the insect.

27. The mutant of claim 15 wherein at most one wild-type *chico* gene is found in the head region of the insect only.

28. Use of an insect according to claim 15 as a means in screening compounds for modulating diseases.

29. Use of an insect according to claim 15 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

30. Use according to claim 22 characterized in that the disease is diabetes type 2.

31. A method for generating a mutant insect, characterized in that adult animals are treated with a mutation generating means under mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects[, in particular *chico* mutant insects,] and that viable offsprings with altered cell number, cell size, developmental time [and/]or lipid levels are cultivated under suitable conditions.

32. The method of claim 31 wherein the adult animals are males.

33. The method of claim 31 wherein the treated insects are crossed with *chico* mutant insects.

34. The Mutant of claim 25 which is a *Drosophila* mutant.

## IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES

### Technical Field

The present invention concerns a tool for the investigation of diseases, in particular type-2 diabetes. The invention especially concerns an in vivo model that enables e.g. the screening of compounds suitable for therapy and diagnosis.

10

### Background Art

Due to its homology with man, *Drosophila* might be a very useful in vivo model for the investigation of human diseases and for the drug screening, as long as the target to be investigated leads to an easily detectable change in the fly, such as size reduction.

Factors influencing the growth have already been extensively studied.

Much of the knowledge about growth regulation stems from studies done using tissue culture cell lines. A large number of peptide growth factors have been identified that stimulate cell division and survival of cultured cells. These observations have led to the hypothesis that regulation of overall growth is controlled primarily by coordinating cell cycle progression and cell survival (Raff, 1996). Although during development, the regulation of the cell cycle is tightly coupled to morphogenetic events (Edgar et al, 1994), several lines of evidence suggest that it may not be the primary determinant of growth regulation. Overall growth of an organ appears to be monitored by measuring total organ tissue volume and not by counting cell divisions. In mosaic wings consisting of haploid and diploid cells, haploid cells produce a normal sized compartment consisting of twice the number of cells (Santamaria, 1983). Moreover, if mitosis is blocked by

use of a temperature sensitive mutation in *cdc2* (Weigmann et al., 1997) or by overexpression of RBF, which is a negative regulator of the cell cycle (Neufeld et al., 1998), the result is normal sized compartments consisting 5 of fewer but larger cells. Conversely, accelerating the cell cycle by overexpression of E2F, a positive cell cycle regulator produces more and smaller cells but does not alter clone size (Neufeld et al. 1998). Thus, changing the length of the cell cycle does not directly 10 affect overall organ growth, which indicates that cellular growth can occur independently of cell cycle control.

In higher vertebrates, hormones and growth factors play an important role in the control of overall 15 growth because they orchestrate cell growth, cell cycle, and cell survival. Reducing or increasing levels of growth hormone or of its mediators, IGF-1 and its receptor (IGFR), dramatically influence body and organ size (for review see Stewart and Rotwein, 1996). The control of 20 cell survival can be an essential factor influencing overall growth (Raff, 1996).

Overall growth (and in some cases cell size) is also affected by the availability of nutrients. Many 25 organisms have developed special survival strategies for periods of growth during low nutrition. Under inadequate nutritional conditions yeast cells, for example, reduce growth and divide at a smaller size (Thomas and Hall, 1997), whereas nematodes like *C. elegans* enter a diapause called the dauer stage (reviewed in Riddle, 1988; Cassada 30 and Russel, 1975). When in this state, larvae arrest development in a sexually immature stage, alter their metabolism to increase the storage of fat, and live up to three times as long as under non-starved conditions (Cassada and Russel, 1975). Dauer formation in *C. elegans* 35 is dependent on the cooperation of the insulin and TGF- $\beta$  signalling pathways (Kimura et al., 1997). Raising *Drosophila* under adverse food conditions also results in

the production of small flies with fewer and smaller cells (Robertson, 1959; Bryant and Simpson, 1984). Still, little is known in higher organisms about how growth is controlled at the cellular level. In *Drosophila*, a class 5 of mutations known as *Minutes* (*M*) dominantly delay development, and in some cases result in reduced body size. Some of the *M* genes encode ribosomal proteins and are thought to slow down growth by reducing protein synthesis (Lindsley and Zimm, 1992). Partial loss of 10 function mutations in the *Drosophila myc* gene, *diminutive*, cause a reduction in overall body size (Gallant et al., 1996).

There has also already been described a P element induced *Drosophila* mutation, *fs(2)4<sup>1</sup>*, as a female 15 sterile, male fertile, mutation (Berg and Spradling, 1991). However, there is nothing disclosed about size differences or the place of the P-element induced mutation.

Thus, none of the documents of the state of 20 the art suggests any applicability of such flies in the investigation of human diseases and/or for drug screening.

It is therefore still very much desired to 25 get an *in vivo* model for such investigations.

#### Disclosure of the Invention

It has now surprisingly been found that the mutant strain, the phenotype of which was described by 30 Berg and Spradling in 1991, after 7 years of storage lost its viability. The originally described female sterile phenotype could be restored by recombination. After recombination, two further phenotypes associated with the defect *fs(2)4<sup>1</sup>* could be observed: Homozygous animals are 35 reduced in size and adult flies have increased lipid levels. Furthermore it was discovered that the mutation

is located in the gene coding for the homolog of the insulin receptor substrate (IRS 1-4).

5 Due to the observed reduction in the body size, the gene affected by the P element and the mutant animal, in particular the mutant *Drosophila*, with a size reducing defect in said gene, are named *chico* which means small boy in Spanish.

The observed alterations in the body size and other characteristics of the mutant make such mutant animals very useful tools in the investigation of interactions with and mutations of the insulin signaling pathway.

Thus, one object of the present invention was to provide a method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, wherein a viable insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal. Preferred animals for use in such method are animals with reduced *chico* function, e.g. with at least one nucleotide sequence being a *chico* mutation.

Another object of the present invention was to provide the *chico* gene and *chico* mutations, in particular size reducing *chico* mutations. *Chico* is of particular interest, since also homozygosity for *chico* causes only semi-lethality. Additionally, an overall delay in development has been observed. Homozygous *chico* animals eclose two or three days after their heterozygous siblings. Under noncrowded culture conditions, homozygous *chico* mutant females can produce few viable progeny lacking both maternal and zygotic *chico* function.

In the scope of the present invention, animal means insects, whereby preferred insects are flies and a preferred fly is *Drosophila*. Where in the scope of the further general description fly or *Drosophila* is 5 mentioned, it has to be understood that - in not preferred embodiments of the present invention - also other animals of the above definition are encompassed in the respective disclosure.

The fact that insects with a mutation within 10 the insulin signaling pathway show altered characteristics is e.g. shown in that mutant flies homozygous for *chico* are markedly reduced in size but survive. This shows that a total loss of *chico* activity is not lethal. Obviously, the insulin receptor (INR) 15 pathway is thus that *chico* can - at least partially - be bypassed.

Due to this finding, *chico* mutant animals are not only suitable for drug screening, but also enable the search for possible further defects in the INR pathway or 20 therewith interacting factors.

While for drug screening flies with two inactive *chico* mutants, one inactive *chico* mutant and one *chico* gene lost, or both *chico* genes lost are preferred, also flies with a reduced *chico* activity can be used as 25 long as the mutant flies are sufficiently distinguishable from wild-type flies.

Such flies with reduced *chico* activity can either have two *chico* mutations with reduced activity both, one *chico* mutation with no and one *chico* mutation 30 with reduced activity, or one *chico* totally lacking and one *chico* mutation with reduced activity.

Besides of drug screening, such *chico* mutant flies can also be used as sensitized model systems to find other key components in the INR pathway.

35 Although heterozygous *chico* flies with one functional *chico* are not easily distinguishable from wild-type flies, they are interesting models for finding

further key components in the INR pathway, whereby flies sensitized in *chico* and having a further non-lethal defect in another compound involved in the INR pathway, are again useful model systems for drug screening and

5 search for further key components.

Flies comprising, besides *chico*, further mutations can be obtained by several methods known to the skilled person such as mutations induced by P element, chemical compounds, radiation etc. If a mutation of a

10 known key component shall be introduced, this can furthermore be performed by destroying at least one respective wild-type gene and insertion of the desired mutation.

The preferred animal - as already mentioned

15 above - is *Drosophila* due to the great knowledge on this fly, the high conservation of the genome and the fast reproduction. However, the high conservation makes also other insects suitable model systems, in particular other flies.

20 The applicability of *chico* mutations is not only particularly broad due to their specific characteristics, but also due to the fact that it is the first coupling element within the cell and thus situated at the very beginning of the cascade of components

25 involved in the INR pathway.

The method of screening for compounds influencing the INR pathway involves *chico* mutant animals such that e.g. a single drug or a combination of two or more drugs is applied to the animal in as early

30 development stage, e.g. to the larvae of said *chico* mutant flies and that at least one difference between treated and non treated animals in the juvenile or adult state, e.g. larvae or flies, respectively, is determined.

The time of the application is not critical.

35 The application can be performed by injection, whereby a preferred method is injection into the egg, and a much preferred method is injection into the larvae. However,

for some applications, injection into the adult animal is also possible.

The determination of differences between treated and non-treated animals can be performed by 5 measuring the weight, the cell size, the cell number or the lipid content per weight. The fact that *chico* affects not either cell size or cell number, but both is a very favorable characteristic if e.g. a second defect were present affecting either the number or the size only.

10 Thus, *chico* mutant flies, whether they have only *chico* mutations or furthermore another mutation in the INR pathway, are very useful tools for the screening of compounds improving the INR signalling pathway.

15

#### Brief Description of the Drawings

The invention will be better understood and objects other than those set forth above will become apparent when consideration is given to the following detailed description thereof. Such description makes reference to the annexed drawings, wherein:

Figure 1A shows the body size reduction of homozygous mutant animals at different development stages, whereby *Drosophila* with one wild-type *chico* (+) and one inactive *chico* allele (-) are marked as (+/-), *Drosophila* with two inactive *chico* alleles as (-/-) and control flies with two wild-type *chico* as (++)<sup>2</sup>, and whereby the *chico*<sup>-/-</sup> egg was derived from heterozygous *chico* females in which *chico*<sup>-/-</sup> germline clones had been generated. The *chico*<sup>1</sup> allele (P element insertion allele) was used for germ-line clones. In comparison, a heterozygous *chico* mutant egg (*chico*<sup>+/</sup><sub>-</sub>) is shown. Homozygous *chico*<sup>-/-</sup> larvae, pupae and adults were derived from heterozygous flies carrying the *chico*<sup>2</sup> allele.

35 Figure 1B shows the body weight of individual flies (n = 20) whereby the weights of y w control flies

(+/+), heterozygous (+/-) and homozygous mutant (-/-) *chico* flies are shown.

Figure 2 represents comparison of the cell size distribution of heterozygous (+/-) and homozygous 5 mutant (-/-) *chico* wing disc cells determined by FACS analysis, whereby

Figure 2A represents dot blots of heterozygous (+/-) *chico* wing disc cells displaying forward scatter (FSC), which is a measurement for cell 10 size, and side scatter (SSC), which is a measurement for cell granulation, and whereby

Figure 2B is an analogue representation as Figure 2A for homozygous (-/-) *chico* wing disc cells.

Figure 2C is a histogram that displays cell 15 size (FSC) and cell number. Comparison of the mean value of the FSC in Figure 1A and Figure 1B of the gated cell population (R1) reveals that the mean value of the FSC of homozygous mutant *chico* cells is reduced by 10-14 percent in three independent experiments compared with 20 the mean value of the FSC of heterozygous cells.

Figure 3A shows the genomic structure of the *chico* locus at 31B-C with the putative transcriptional start site lying 221 bp 3' from the end of *bsk* encoding DJNK. *ME31B* encodes a DEAD box RNA helicase (de Valoir et 25 al., 1991). Comparison of the genomic and cDNA sequence revealed that the *chico* transcript contains 9 exons with the putative translational start site in the second exon. Black boxes represent translated exons and open boxes indicate untranslated exons. See text for details 30 concerning the P element insertion, the deficiency chromosome, and the rescue constructs. H = HindIII; E = EcoR1.

Figure 3B shows the translated amino acid sequence wherein the black-boxed sequence represents the 35 PH domain and the grey-boxed sequence the PTB domain, respectively, and wherein the putative DRK binding site

(YQN) and the two putative p60 PI3K binding sites (YIPM and YLEM) are highlighted.

Figure 3C shows a PH and PTB domain alignment, wherein the PH domain and the PTB domain of 5 CHICO were aligned to human IRS-1,2,4 and mouse IRS-3, and wherein the dark boxes indicate amino acid identity, while the grey boxes indicate amino acid similarity. The lowercase letters in the consensus line represent identity in 3-4 of the proteins, while upper case letters 10 represent identity in all proteins. The percentage identity was calculated by comparing CHICO individually to each mammalian IRS, and then averaging the four separate identities.

Figure 4A is a tangential section through an 15 eye containing a CHICO (--) clone, whereby the *chico* (--) clone is recognized by the lack of pigment (bright ? passages). Within the clone, all photoreceptor (PR) cells are reduced in size by about 50 percent compared with wild-type PR cells (dark). At the border of the clone 20 ommatidia composed of wild-type and small *chico*-- mutant PR cells (arrow head) are visible, indicating that CHICO controls cell size autonomously. The numbers represent PR cells R1-R7.

Figure 4B is a comparison of wild-type flies 25 with flies in which the *chico* function in the eye imaginal disc cells has been removed, thereby generating flies with a strongly reduced head capsule and reduced eyes, whereas the proboscis and the rest of the body are of wild-type size. The flies compared were of the 30 following genotypes: (B, left panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40; P(w<sup>+</sup> chico genomic rescue construct pCSR4)/+*, (B, right panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40*, (C, scanning electron 35 micrograph, left panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / CyO*, (C, scanning electron micrograph, right panel) *y w ey-Flp; chico*<sup>1</sup> *FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40*.

Figure 4C is an enlarged view of the head region of Figure 4B.

Figure 5A shows the fresh and dry weight of individual wild-type (+/+) , heterozygous (+/-) , and 5 homozygous (-/-) *chico* mutant males, whereby measurement was made of individual adult males (n = 10) reared under the same growth conditions and analyzed three days after eclosion. The dry weight of wild-type, heterozygous and homozygous mutant males is approximately 28 percent of 10 the corresponding fresh weight.

Figure 5B shows lipid, protein and glycogen contents of the same analytical group as in Figure 1A. As can be seen homozygous *chico* mutant (-/-) males contain almost twice as much lipid calories per milligram fresh 15 weight compared with heterozygous (+/-) or wild-type (+/+) flies.

#### Modes for carrying out the invention

20 In order to use insects, in particular *Drosophila* mutants as *in vivo* monitoring system, the function of the defect gene and differences between wild-type *Drosophila* and *chico* mutant *Drosophila* have been studied.

25 Thereby it was found that *chico* encodes a homologue of vertebrate insulin receptor substrates, IRS1-4.

The insertion site of the P element in *chico*<sup>1</sup> was mapped 1.5 kb downstream of the *bsk* gene (Figure 3A). 30 Isolation and analysis of partial cDNA clones, a full length EST clone and the corresponding genomic sequence flanking the P element insertion, indicated that the *chico* gene consists of a single transcription unit of 3.6 kb with 9 exons. The P element insertion is located 80 bp 35 downstream of the putative translation initiation site in the PH domain (see below). The open reading frame codes for a protein product of 967 amino acids with a

calculated molecular weight of 97 kd. The CHICO amino acid sequence exhibits the strongest similarity with members of a family of vertebrate insulin receptor substrate proteins known as IRS1-4. Vertebrate IRS family members are characterized by an N-terminal pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain and by a number of phosphotyrosine motifs that can serve as docking sites for SH2-containing proteins (for review see Yenush and White, 1997).

The cDNA sequence (SEQ ID NOs 1, 2) of wild-type chico is shown in Table 1 together with the respective protein sequence, (SEQ ID NOs 2, 3) and the genomic DNA sequence (SEQ ID NO 4) is found in Table 2 below.

While the cDNA sequence shows the coding sequence only, the genomic sequence comprises functional flanking parts.

Furthermore, it has to be understood that all sequence related statements - also without specific mention - also concerns the complementary strand.

Table 1: cDNA and Protein Sequence

5	154/1 214/21	184/11 244/31
10	ATG GCA TCA ATA TCG GAT GAC GGC ATG GCG CTG AGT GGC TAC CTC AAG AAG CTG AAG ACC ATG AAG AAG AAG TTC TTT GTG CTG TAC GAG GAG ACG AGC ACT TCG GCA GCC CGG CTG GAG	
15	Met ala ser ile ser asp asp gly met ala leu ser gly tyr leu lys lys leu lys thr met lys lys phe phe val leu tyr glu glu thr ser thr ser ala ala arg leu glu	304/51
	274/41 334/61	364/71
20	TAC TAC GAT ACC GAA AAG AAG TTC CTG CAA AGA GCC GAG CCA AAA AGG GTT ATA TAT CTG AAG AAT TGC TTC AAC ATC AAT CGC CGT TTG GAC ACC AAG CAT AGA TTT GTC ATT GTG CTC	
25	tyr tyr asp thr glu lys lys phe leu gln arg ala glu pro lys arg val ile tyr leu lys asn cys phe asn ile asn arg arg leu asp thr lys his arg phe val ile val leu	424/91
30	394/81 454/101	484/111
35	TCC TCC AGA GAC GGT GGA TTC GGC ATC GTT CTC GAG AAC GAA AAT GAT TTA CGC AAA TGG TTG GAC AAA CTA CTA GTT CTA CAA AGG AAC ATA GCC AAT TCG AAT GGA ACA GCG CAC TCA	
40	ser ser arg asp gly gly phe gly ile val leu glu asn glu asn asp leu arg lys trp leu asp lys leu leu val leu gln arg asn ile ala asn ser asn gly thr ala his ser	544/131
	514/121 574/141	604/151
45	CCT TAT GAC CAC GTT TGG CAA GTT GTC ATT CAA AAG AAG GGT ATT TCG GAG AAA GTT GGA ATC ACC GGA ACC TAC CAC TGT TGC CTT ACT TCA AAA TCC CTG ACA TTC GTG TGC	
50	ATT GGA pro tyr asp his val trp gln val val ile gln lys lys gly ile ser glu lys val gly ile thr gly thr tyr his cys cys leu thr ser lys ser leu thr phe val cys	664/171
55	ile gly 634/161 694/181	724/191

CCG GAG AAG ACG CCC AAT GGC GAG GAT CGC GTT GCG AGC ATT GAA ATA CTT  
TTG ACC  
ACG ATC AGG CGA TGC GGT CAT GCA TCC CCA CAA TGT ATA TTC TAC GTG GAA  
CTT GGC  
5 CGC CAA  
pro glu lys thr pro asn gly glu asp arg val ala ser ile glu ile leu  
leu thr  
thr ile arg arg cys gly his ala ser pro gln cys ile phe tyr val glu  
leu gly  
10 arg gln  
754/201 784/211  
814/221 844/231

AGT GTC TTG GGA TCT GGT GAT CTG TGG ATG GAG ACG GAT AAC GCA GCT ATT  
15 GCT ACT  
AAT ATG CAC AAC ACG ATA CTG AGC GCT ATG TCA GCC AAA ACA GAG TCG AAC  
ACG AAT  
TTA ATA  
ser val leu gly ser gly asp leu trp met glu thr asp asn ala ala ile  
20 ala thr  
asn met his asn thr ile leu ser ala met ser ala lys thr glu ser asn  
thr asn  
leu ile  
874/241 904/251  
25 934/261 964/271

AAC GTT TAT CAG AAT AGA CCT GAC TTA AGT CAC GAG CCC ATG AGA AAG CGA  
TCG TCG  
TCT GCA AAC GAA GCA TCG AAG CCG ATA AAC GTA AAT GTC ATA CAA AAT AGT  
30 CAA AAC  
TCT CTC  
asn val tyr gln asn arg pro asp leu ser his glu pro met arg lys arg  
ser ser  
ser ala asn glu ala ser lys pro ile asn val asn val ile gln asn ser  
35 gln asn  
ser leu  
994/281 1024/291  
1054/301 1084/311

40 GAA TTG CGC AGC TGC AGT TCG CCC CAT AAC TAT GGT TTC GGC AGA GAG AGA  
TGC GAT  
AGC TTA CCA ACC AGA AAT GGA ACC CTA AGC GAG TCC AGC AAT CAA ACG TAC  
TTT GGT  
TCC AAC  
45 glu leu arg ser cys ser ser pro his asn tyr gly phe gly arg glu arg  
cys asp  
ser leu pro thr arg asn gly thr leu ser glu ser ser asn gln thr tyr  
phe gly  
ser asn  
50 1114/321 1144/331  
1174/341 1204/351

CAT GGA CTG CGA TCC AAT ACT ATA TCT GGC ATC CGT CCG CAC TCA ACC AAC  
AAG CAT  
55 AGT AAT AGT CCA ACG TTC ACC ATG CCA TTA AGA TGC TCA GAA TCC GAA GAG  
TCA TCA  
ATT AGT  
his gly leu arg ser asn thr ile ser gly ile arg pro his ser thr asn  
lys his

ser asn ser pro thr phe thr met pro leu arg cys ser glu ser glu glu  
ser ser  
ile ser  
1234/361 1264/371  
5 1294/381 1324/391

GTC GAT GAA TCC GAC GAC AAC GGC AGT TTT AGC CAC TAC AGA TTA AAC ACG  
CGG TCA  
TCT GAG ACG GCA ATT CCT GAG GAA AAC ATT GAT GAC TTT GCC AGT GCG GAA  
10 TTA TTT  
AGC AAA  
val asp glu ser asp asp asn gly ser phe ser his tyr arg leu asn thr  
arg ser  
ser glu thr ala ile pro glu glu asn ile asp asp phe ala ser ala glu  
15 leu phe  
ser lys  
1354/401 1384/411  
1414/421 1444/431

20 GTC ACC GAA CAA AAT GTA AGT GAC GAA AAC TAC ATA CCG ATG AAT CCA GTC  
AAT CCT  
ACC GAT GCT ATC CAT GAA AAG GAG AAG GCT GAT ATG CAG AGA TTG GAA GAT  
GCT TCG  
CTG CAT  
25 val thr glu gln asn val ser asp glu asn tyr ile pro met asn pro val  
asn pro  
thr asp ala ile his glu lys glu lys ala asp met gln arg leu glu asp  
ala ser  
leu his  
30 1474/441 1504/451  
1534/461 1564/471

TTC AAC TTT CCG GAG CAC GCG TCG GAA AAG CTT GCT AAG GAT TTT GAT CTG  
GAC TCT  
35 GAT AAC CAA TGC TGT CGT CCC ATT CGC GCC TAT TCG ATA GGC AAC AAG GTT  
GAG CAT  
TTA AAG  
phe asn phe pro glu his ala ser glu lys leu ala lys asp phe asp leu  
asp ser  
40 asp asn gln cys cys arg pro ile arg ala tyr ser ile gly asn lys val  
glu his  
leu lys  
1594/481 1624/491  
1654/501 1684/511

45 TTT AAT AAG CGC CTG GGA CAC TTG AAT GAT ACG GGA CAG AAT CCG AAT CGC  
GTG CGA  
GCC TAC TCG GTT GGC TCC AAA TCG AAG ATA CCG CGC TGC GAC CTG CAG CGA  
GTG GTC  
50 CTC GTG  
phe asn lys arg leu gly his leu asn asp thr gly gln asn pro asn arg  
val arg  
ala tyr ser val gly ser lys ser lys ile pro arg cys asp leu gln arg  
val val  
55 leu val  
1714/521 1744/531  
1774/541 1804/551

60 GAG GAC AAT AAA CAT GAG TTC ACA GCG AAT AGG AGT CAG AGT AGC ATT ACC  
AAG GAA

GGA ACC AGC TAT GGC AGC AGT GCC AAT CGA CAA AAG AAG TCC ACA AGT GCT  
 CCA CTC  
 CTC AGT  
 glu asp asn lys his glu phe thr ala asn arg ser gln ser ser ile thr  
 5 lys glu  
 gly thr ser tyr gly ser ser ala asn arg gln lys lys ser thr ser ala  
 pro leu  
 leu ser  
 1834/561 1864/571  
 10 1894/581 1924/591

CTG AAG AAC CAG ATA AAC TCC GAC CGA ATG AGT GAC TTA ATG GAA ATT GAT  
 TTT TCA  
 CAA GCA ACC AAT TTG GAA AAG CAG AAG TTC ATC AAG AAT AAT GAA ATT CCG  
 15 AAA TAC  
 ATT GAA  
 leu lys asn gln ile asn ser asp arg met ser asp leu met glu ile asp  
 phe ser  
 gln ala thr asn leu glu lys gln lys phe ile lys asn asn glu ile pro  
 20 lys tyr  
 ile glu  
 1954/601 1984/611  
 2014/621 2044/631

25 AAC GTG TTC CCA AAA GCC CCG CGA ACG GAT AGC TCC AGC CTA ACT CTG CAC  
 GCC ACA  
 AGT CAA AAG GAC ATT TTC AAT GGC ACC AAA CTA AAT AAC ACT GCG ATC ACA  
 TCC GAG  
 GAT GGT  
 30 asn val phe pro lys ala pro arg thr asp ser ser ser leu thr leu his  
 ala thr  
 ser gln lys asp ile phe asn gly thr lys leu asn asn thr ala ile thr  
 ser glu  
 asp gly  
 35 2074/641 2104/651  
 2134/661 2164/671

TAC CTC GAG ATG AAG CCA GTC GGT AAT GGA TAC ACT CCC AGT TCG AAT TGC  
 CTG CCA  
 40 ATG AAA GTG GAG AAA CTC AAG CTA TCC GAC TAT CAG ACA GCA CCG CCA CTC  
 ACC GCA  
 ACA GCC  
 tyr leu glu met lys pro val gly asn gly tyr thr pro ser ser asn cys  
 leu pro  
 45 met lys val glu lys leu lys leu ser asp tyr gln thr ala pro pro leu  
 thr ala  
 2194/681 2224/691  
 2254/701 2284/711

50 GCA CCA GTG CAC GAT TTA AAC AAA ATT AGC ACA TAC AAT ATA TCC GCT GAG  
 AAA TGG  
 AGA GAA CAG CCC AGC AGA AGC GAG GAA AAG AAG TCG AAC TCG CCA TTG AAT  
 GAC AAC  
 55 ACC TTT  
 ala pro val his asp leu asn lys ile ser thr tyr asn ile ser ala glu  
 lys trp  
 arg glu gln pro ser arg ser glu glu lys lys ser asn ser pro leu asn  
 asp asn  
 60 thr phe

2314/721	2344/731	
2374/741	2404/751	
AGC TCG AAA CCC ACA AAT GTC GAG AGT ACA AGC AAA AGC CAT GAT GTT CAT		
5	TCA GCA	
AAT CAA ATT GAT TGC GAG AAA GTG TGC GCG CAG AGC AGC GAT AAG CTA AAT		
AAT CAT		
CTG GCC		
ser ser lys pro thr asn val glu ser thr ser lys ser his asp val his		
10	ser ala	
asn gln ile asp cys glu lys val cys ala gln ser ser asp lys leu asn		
asn his		
leu ala		
15	2434/761	2464/771
	2494/781	2524/791
GAC AAG ATT GTC GAG AAC AAC AAT TTG GAT ATA GGC GGG CAT GAG GAA AAG		
AAG TTG		
GTT CAT TCG ATA AGC AGC GAA GAC TAC ACA CAA ATC AAG GAC AAA TCG AAT		
20	GAT TTC	
ACA AAA		
asp lys ile val glu asn asn leu asp ile gly gly his glu glu lys		
lys leu		
val his ser ile ser ser glu asp tyr thr gln ile lys asp lys ser asn		
25	asp phe	
thr lys		
2554/801		2584/811
2614/821		2644/831
30	TTT AAC GAA GCC GGC TAC AAA ATT CTG CAA ATT AAA AGC GAC AGC TCA CTC	
ATC TCA		
TCG AAG CTA TAC CAA AAG GGT ATA CAC AAG GAT AAC TTG GAG CGT TCG CAG		
AGA CTT		
ACA GAG		
35	phe asn glu ala gly tyr lys ile leu gln ile lys ser asp ser ser leu	
ile ser		
ser lys leu tyr gln lys gly ile his lys asp asn leu glu arg ser gln		
arg leu		
thr glu		
40	2674/841	2704/851
2734/861		2764/871
AGT GTG AAT ACG ATT CCC GAT AAT GCC ACC GCC ACC GCG GTG AGC AGC AGC		
TCA CTC		
45	ACC AAA TTC AAT ATA AAT TCA GCA AAG CCA GCC GCC GCC GAT TCG CGT	
AGC ACT		
GGC ACA		
ser val asn thr ile pro asp asn ala thr ala thr ala val ser ser ser		
ser leu		
50	thr lys phe asn ile asn ser ala lys pro ala ala ala ala asp ser arg	
ser thr		
gly thr		
2794/881		2824/891
2854/901		2884/911
55	GAT CCA AGT ACA CCA CAG AAC ATT CTA CAG ATT AAA GAT TTG AAT TTC CCC	
TCA AGG		
TCG TCG TCT CGC ATA TCC CAG CCG GAG CTG CAC TAC GCC AGC CTA GAT CTT		
CCC CAT		
60	TGC AGT	

asp pro ser thr pro gln asn ile leu gln ile lys asp leu asn phe pro  
ser arg  
ser ser ser arg ile ser gln pro glu leu his tyr ala ser leu asp leu  
pro his

5 cys ser  
2914/921  
2974/941

2944/931  
3004/951

GGC CAA AAT CCA GCT AAA TAC CTG AAG AGA GGA TCA CGC GAA TCG CCG CCG  
10 GTG TCC  
GCA TGC CCG GAG GAT GGG AAT ACC TAT GCG AAA ATC GAC TTT GAC CAA TCC  
GAC TCC  
TCT TCC  
gly gln asn pro ala lys tyr leu lys arg gly ser arg glu ser pro pro  
15 val ser  
ala cys pro glu asp gly asn thr tyr ala lys ile asp phe asp gln ser  
asp ser  
ser ser  
3034/961  
20 TCC TCA TCG AAC ATA TTT AAT ACG TAA  
ser ser ser asn ile phe asn thr OCH

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

Table 2: Genomic DNA sequence

5 AGAACGACTTTTCCCTTAGTCAGTCACAAGAAAACAAAGCTTACCA  
 ACAATACGGCGTGTATTGTTAAATTATTACAACAAATAAAATATTCAAAT  
 TGTATTAAAAATATAGTAACCATTAAAAAATAAAATCAATATGCGAAC  
 TTTGTAATTCTTACTCATCCTGTGTTTGAGCCCGCTTCTTAAGTTA  
 AATCGTTAAAATACCACTGTTAACATCATTCTGCTGATTTCAGGAGCT  
 AATTACATTAAATCTTGTATAAATTCTATAAAATTTAAATGGAAATGTT  
 10 TAACCACATAAAATATTGGGTATATAAAGTCGATACATACTTTAAAAT  
 TTTGTTCTACAGAAATATGGAAAGTAGATAATTAGTTACCGATTAAA  
 ACATTCTAAAATACAAAAAATTAAATGATGATTAAATAAAACTGTT  
 TATACTAAATTAAACGAAACAAACGGTCATTGATAACTCAATTAGTAT  
 CGAATAAGCCGGCGTGTAAATCGGGTTGGCAACTCTCACCCGTGTAGAGA  
 15 TCGGGATGGCAACTTCGTATTGTTATTCTATGCTGCGATAACGATAACA  
 GCAAAGTGTCACTCGGAATAAATGTGGGTTGATAATAAAGAATTGCGTT  
 GGTGAACAATAATAACAAATGCTAAATGTATCGCGCGATAACTAGTA  
 AACACTGATTCGCGCATATCGGGCATACGGCAGCTAGACGTCTTAGGT  
 AACACATTCCCAGCCACATTGGCGTTGAGGTATTATTCATATCCAT  
 20 GTGCGTTGTAATGATACCACCAAGAGTGTGCCATATGTATCGTGTGTTG  
 TACATACATGCCTACGGGGAAAAATAACTCGCAGATACTATGTATGTA  
 GATGTATTAGAATTCCACAGATATATGTACATATAAATATATATAT  
 TTATGATGCTCATCTATAAAACAAATATGTACAAACATA CGCGCAG  
 TACCTATGTATGTACATATACTACATATGTATAATAAAATGAG  
 25 CATCTAGCTCGGGTATCTTAATGCAATGCGCAGAAACCTGAAAACGAAA  
 TAAACAATCTTACAGCGCCAGCACAGTGAGCCAATTATGAATTACAAT  
 TCCACATCCAATTCCGATTCCGATTCCATCGCTTACATCCTAATTGCA  
 ATACGTCGCGCCGCGTAAGCTGCACTCGAATATTGACATAACGACGTA  
 TTGCGTGTGTTGATTGCGATTCCGATGCTGATGTTGACAGACGGCAAG  
 30 GATTTTTTGCAGCCGACATTGCAATGCTTTGCGTGTGCTGTTGTT  
 TGAAAAGCGATTGTTGTTCCGGCAGTTGAAATGTTTGCTGCTGTT  
 GCTTAGAAAAGCAAATGTATTGCAACAAACTCGTGTGTTCTACATTAGTA  
 AAGCCTATAACTTAGGTATATGTTCTAAATTACAATGCAAAAATAAAA  
 AACATTATACTGTGTTGCTCTTAATTGAAAACAGAAAAGTGAAGAC  
 35 CTGCAAATCAAATATGTGTCATATCGCCTACTAATAATATAACACGT  
 CGCCTCCAGGAACATAAGATTGAAATCATGGCATCAATATCGGATGACG  
 GCATGGCGCTGAGTGGCTACCTCAAGAAGCTGAAGACCATGAAGAAGAAG  
 TTCTTGCGCTGTACGAGGAGACGAGCACTCGGCAGCCCGCTGGAGTA  
 CTACGATACCGAAAAGAAGTCTGCAAAGAGCCGAGCCAAGAGGGTTA  
 40 TCTATCTGAAAGATTGCTCAACATCAATCGCCGTTGGACACCAAGCAT  
 AGATTGTCATTGCTCTCCTCCAGAGACGGTGGATTGGCATCGTTCT  
 CGAGAACGAAAATGATTACGCAAATGGTTGGACAAACTACTAGTTCTAC  
 AAAGGAACATAGCCAATTGAAATGGAACAGCGCACTCACCTATGGTATG  
 CCAAATAAACTATAACTACCACTAGTATGAAACCTAAACACTTCATTIC  
 45 ACTTGCAAGACCACTGGCAAGTTGTCATTCAAAGAAGGGTATTGCG  
 GAGAAAGTTGGAATCACCGGAACCTACCACTGTTGCTTACTCTAAAC  
 CCTGACATTGCGTGCATTGGACCGGAGAAGACGCCAATGGCGAGGATC  
 GCGTTGCGAGCATTGAAATACTTTGACCACTGAGGCGTTAGTTGTT  
 GCCAGAAAACGTCAAGGGATTGAAAATAATTGGAACCTAATTTCAGAT  
 50 GCGGTCACTGCATCCCCACAATGTATATTCTACGTGGAACCTGGCCCAA  
 AGTGTCTTGGATCTGGTGTCTGTGGATGGAGACGGATAACGCAGCTAT  
 TGCTACTAATATGCACAACACGATACTGAGGTATTAGCTCTCATTACAA  
 CTAATCCAAGATTCTCATGATCATCCTACAAACGACATAGATAGTTAAG  
 ATATCTCCCAGTTAACATTAAATTCTGTGGGTTTTCTTCAGCGCT  
 55 ATGTCAGCCAAAACAGAGTCGAACACGAATTAAACGTTATCAGAA  
 CAGACCTGACTTAAGTCACGAGCCCATGAGAAAGCGATCGTGTGCAA  
 ACGAACGATCGAAGCCGATAACGTAATGTACACAAATAGTCAAAC

TCTCTCGAATTGCGCAGCTGCAGTCGCCCATAACTATGGTAAATACCT  
5 CAAATGTATGTTAACGCAAAATTAATCAAACGCAATCGTTCAGGTT  
CGCAGAGAGAGATGCGATAGCTTACCAACCAGAAATGGAACCTAAGCG  
AGTCCAGCAATCAAACGTACTTGGTCCAACCATGGACTGCGATCCAAT  
10 ACTATATCTGGCATCCGTCGCACTCAACCAACAAGCATAGTAATAGTCC  
AACGTTACCATGCCATTAAGATGCTCAGAATCCGAAGAGTCATCAATTA  
GTGTCGATGAATCCGACGACAACGGCAGTTAGCCACTACAGATTAAG  
TGCCTGCTATCAAATAATTATTTAATAATAATCACCATTCAATT  
CTAGCACGGGTCATCTGAGACGGCAATTCTGAGGAAAACATTGATGAC  
15 TTTGCCAGTGCAGAATTATTTAGCAAAGTCACCGAACAAAATGGTAAGCC  
AAACACAAAAACAATTTTAACATGAAAAGTAGCTAATCAATTGGCTT  
GTTTAACTGCAGTAAGTGACGAAAACATACATACCGATGAATCCAGTCAT  
CCTACCGATGCTATCCATGAAAAGGAGAAGGCTGATATGCAGAGATTGGA  
AGATGCTTCGCTGCATTCAACTTCCGGAGCAGCGTCGGAAAAGCTTG  
20 CTAAGGATTITGATCTGGACTCTGATAACCAGTGAGTACACATTTCGCTT  
CAACTGTGCCACGTAATGCAATCAATCACATCTGTTACAGATGCTGTCG  
TCCCATTGCGCCTATTGATAGGCAACAAGGTTGAGCATTAAAGTTTA  
ATAAGCGCCTGGGACACTGAATGATAACGGGACAGAAATCGAATCGCTG  
CGAGCCTACTCGGTTGGCTCCAAATCGAAGATAACCGCGTCGACCTGCA  
25 GCGAGTGGTCCTCGTGGAGGACAATAAACATGAGTTCACAGCGAATAGGA  
GTCAGAGTAGCATTACCAAGGAAGGAACCGAGCTATGGCAGCAGTGC  
CGACAAAAAGAAGTCCACAAGTGCTCCACTCCTCAGTCTGAAGAACCGAGAT  
AAACTCCGACCGAATGAGTGACTIONTAATGAAATTGATTTCACAAGCAA  
CCAATTGAAAAGCAGAAGTTCATCAAGAATAATGAAATTCCGAAATAC  
30 ATTGAAAACGTGTTCCAAAAGCCCCGGAACGGATAGCTCCAGCCTAAC  
TCTGCACGCCACAAGTCAAAAGGACATTTCATGGCACCAAACATAATA  
ACACTGCGATCACATCCGAGGATGGTACCTCGAGATGAAGCCAGTCGGT  
AATGGATAACTCCAGTTGCAATTGCTGCCATGAAAGTGGAGAGGCT  
CAAGCTATCCGACTATCAGACAGCACCGCCAATCACCGCAACAGCCGAC  
CAGTGCACGATTAAACAAAATTAGCACATACAATATATCCGCTGAGAAA  
TGGAGAGAACAGCCCAGCAGAAGCGAGGAAAAGAAGTCGAACCTGCCATT  
GAATGACAACACCTTGGCTGAAACCCACAAATGTCGAGAGTACAAGCA  
AAAGCCATGATGTTCATTCAGCAAATCAAATTGATTCCGAGAAAGTGTG  
GGCAGAGCAGCGATAAGCTAAATATCTGGCCACAAGATTGTCGAGAA  
35 CAACAATTGGATATAGCGGGCATGAGGAAAAGAAGTTGGTICATTGCA  
TAAGCAGCGAAGACTACACACAAAATCAAGGACAAATCGAATGATTCA  
AAATTAAACGAGCCGGCTACAAAATTCTGCAAATTAAAGCGACAGCTC  
ACTCATCTCATCGAAGCTATACCAAAAGGGTATACACAAGGATAACTGG  
AGCGTTCGCAGAGACTTACGGAGAGTGTGAATACGATTCCGATAATGCC  
40 ACCGCCACCGCGGTGAGCAGCAGCTCACTCACCAAAATTCAATATAATT  
AGCAAAGCCAGCCGGCGCCGATTCCGCTAGCAGTGGCACAGATCCAA  
GTACACCACAGAACATTCTACAGATTAAAGATTGAAATTCCCTCAAGG  
TCGTCGTCTCGCATATCCCAGCCGGAGCTGCACTACGCCAGCCTAGATCT  
TCCCCATTGAGTGGCCAAAATCCAGCTAAATACCTGAAGAGAGGATCAC  
45 GCGAATGCCGCCGGTGTCCGATGCCGGAGGATGGAAATACCTATGCG  
AAAATCGACTTGAACCATCCGACTCCTTCTCTCATCGAACATATT  
TAATACGTAAAGTTGAAATTATGACCCCTATCCTATATATATGATTG  
TTAATATTGTAATTATTGTAATATTAAATTATAATGATCCCTTGA  
50 GACTTTTTTTTTGGACTAAGAAATCACTACTAAAGAAGGGCTTTC  
GAGGGTTAAA

Sequence similarity between CHICO and IRS1-4 is confined to the N-terminal region including the PH domain and the PTB domain. The amino acid identity is 41 percent in the PH domain and 38 percent in the PTB domain (Figure 3B and C). Although there is no significant overall homology within the C-terminal domain, the CHICO protein contains several putative SH2 binding motifs characteristic for IRS family members. Two motifs at positions 411 and 641 fit the consensus binding site (YXXM) for the p85/p60 adaptor subunit of PI110 PI(3)K (Songyang et al., 1993; Weinkove et al., 1997) and one (at position 243) corresponds to the consensus (YXN) for GRB2/DRK binding (Olivier et al., 1993; Songyang et al., 1993).

Owing to the insertion of the P element 80 bp downstream of the translation start site *chico*<sup>1</sup> is likely to be a null mutation. The *chico*<sup>2</sup> allele is a synthetic deletion allele covering the putative translation start site and the regulatory region of *chico* (Figure 3A; see experimental procedures). Flies homozygous for this synthetic *chico* null allele were viable and showed phenotypes indistinguishable from flies homozygous for *chico*<sup>1</sup> (Figure 1B). The mutant phenotype of both alleles is fully rescued by an 8 kb genomic rescue construct encompassing the *chico* transcription unit and its endogenous regulatory sequences (Figure 3A). Therefore the reduction in body size and the female sterility is caused by the loss of *chico* function.

In order to profit from the close similarity of *chico* with IRS 1-4, clearly detectable, and preferably quantifiably differences between *chico* mutants and wild-type flies must exist.

Therefore, specific differences have been searched for and studied.

To quantify size differences in various mutants, the weight of individual flies was determined (Figure 1B). Flies homozygous for the P element (*chico*<sup>1</sup>)

or a synthetic *chico* deletion (*chico*<sup>2</sup>) have a drastic weight reduction (by 65% in females and 55% in males) compared with wild-type control flies of the same age. Body size reduction is observed at all developmental 5 stages, but does not alter the overall proportions of the flies (Figure 1A).

Since the reduction in body and organ size in *chico* mutants could be due to a reduction in the number of cells and/or a reduction in the size of the individual 10 cells, cell number and cell size in the wing was determined. In the wing, each epithelial cell secretes cuticle with a single hair, so that counting the number of hairs and determining their density provides a direct measure of cell number and cell size in the wing. (See 15 Table 3)

Table 3: Cell Size and Cell Number are Affected in Wings of Homozygous Mutan Animals<sup>a</sup>

Genotype	Area <sup>b,c</sup> (10 <sup>6</sup> µm <sup>2</sup> )	1		2		3		4		5		6		7	
		Overall size	Cell density <sup>d</sup> (cells/µm <sup>2</sup> )	Cell density <sup>d</sup> (cells/µm <sup>2</sup> )	Area covered	Cell size reduction per cell <sup>e</sup>	Cell size reduction per cell <sup>e</sup>	Area covered	Cell size reduction per cell <sup>e</sup>	Cell size reduction per cell <sup>e</sup>	Area covered	Cell size reduction per cell <sup>e</sup>	Cell size reduction per cell <sup>e</sup>	Cell number	
Y, w; +/Sp	1.47±0.009	-----	-----	6.38x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	157±2.36	-----	-----	9379	-----	-----	-----	-----	-----	-----	
Y, w; chico <sup>2</sup> /Sp	1.40±0.018	4.8	6.32x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	158±2.90	0	8848	5.7								
Y, w; chico <sup>2</sup> /chico <sup>2</sup>	0.89±0.009	39.5	7.70x10 <sup>-3</sup> ±0.1x10 <sup>-3</sup>	130±1.66	17.2	6853	27								

<sup>a</sup> From females at least eight wings of each genotype were analyzed.

<sup>b</sup> The area of the whole wing was integrated exclusive the alula and the costal cell.

<sup>c</sup> Measured using NIH Image 1.60.

<sup>d</sup> Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 µm<sup>2</sup> area just posterior to the PCV.

<sup>e</sup> Reciprocal of column 3.

<sup>f</sup> Generated by multiplying the values in column 1 by those in column 3.

As shown in Table 3, the 40 percent reduction in the size of *chico* mutant wings is caused by a reduction in both cell number and cell size. Reduction in 5 cell number accounts for 68 percent of the total reduction in wing size. The remaining 32 percent of the reduction in wing size is due to a reduction in the average size of mutant cells. Similar results were obtained for the eye. It could be shown that in 10 homozygous mutant *chico* flies, ommatidial number is reduced by approximately 40 percent: homozygous *chico* flies have only about 480 ommatidia per eye (Table 4) whereas wild-type flies have approximately 780 ommatidia per eye. Therefore, loss of *chico* function reduces body 15 size by means of reducing cell number and cell size.

To test whether the reduction in the size of *chico* mutant cells is also observed during larval stages third instar wing discs of larvae homozygous or heterozygous for *chico* were dissociated and the relative 20 cell size of the two cell populations was determined by FACS analysis (Figures 2A to 2C). A 10-14 percent reduction in the mean of the forward scatter of homozygous *chico* cells compared with heterozygous cells indicates that the size of *chico* imaginal disc cells is 25 also reduced.

Since the effect of loss of *chico* function on the overall body and organ size could be due to a non-autonomous role of *chico* in humoral growth regulation or to an autonomous role in a tissue and cell type specific 30 manner, the autonomy of *chico* was investigated. To test the cell autonomy of the *chico* mutation, clones of genetically marked homozygous mutant *chico* cells in a heterozygous background in the eye were generated (Figure 4A) using the hs-FLP/FRT system (Xu and Rubin, 1993). In 35 each ommatidium, the R1-R6 photoreceptor cells are arranged in an asymmetric trapezoid. The tall side of the trapezoid is formed by photoreceptors R1-R3 facing

anteriorly. The centrally located R7 photoreceptor has a smaller rhabdomere than the six outer cells. Each of these morphological characteristics is retained in *chico* mutant ommatidia. Thus, loss of *chico* function does not impair the specification of cell fate. However, it is striking that the size of each mutant photoreceptor and hence the entire ommatidial unit in the mutant clone, is reduced by more than 50 percent. On the periphery of the clones of homozygous mutant tissue, ommatidia consist of homozygous and heterozygous cells. The genotype of each photoreceptor can be assessed by the presence or absence of red pigment. Small homozygous mutant photoreceptor cells (arrowheads in Figure 4A) coexist with heterozygous cells in the same ommatidium. Remarkably, this does not significantly alter the shape of the ommatidia and the arrangement of the photoreceptors. Autonomy of cell size control is also observed in the wing (data not shown). Therefore, final cell size is autonomously dependent on *chico* function in each individual cell.

In order to further study the effects of *chico*, it was tested whether *chico* affects the size of organs and body parts autonomously. For this testing, *chico* function was selectively removed in the eye imaginal disc using the eye-FLP technique (see Example 4). The results presented here, show that selected removal of *chico* function in the head using the eye-FLP technique reduces head size. This reduced head size phenotype can be used to identify mutations in other genes that affect growth and thus are likely to encode components of the insulin signalling pathway. These mutations thus identify genes that are potential drug targets for human diseases such as type-2 diabetes. The eye imaginal disc gives rise to the compound eye and the head capsule but not to the proboscis. In embryos heterozygous for *chico*, mitotic recombination was selectively induced in the eye progenitor cells by using an FLP recombinase driven by the eyeless-enhancer

(Quiring et al., 1994). Owing to the presence of a recessive mutation affecting cell survival on the *chico*<sup>+</sup> chromosome, *chico* homozygous mutant cells have a proliferative advantage and contribute to the majority of 5 cells in the eye and the head. Thus flies have heads that are largely homozygous for *chico* while the rest of the body is heterozygous. In such flies, the eyes and the head capsule are strongly reduced in size while the proboscis and the rest of the body are of wild-type size 10 (Figure 4B, C). Thus *chico* acts autonomously in the control of cell size and organ size.

It was furthermore investigated whether the reduction in cell number caused by the absence of *chico* function is the result of a prolonged cell cycle time or 15 of an increased rate of apoptosis during development. In order to analyze the behavior of *chico* mutant cells during development, genetically marked homozygous mutant cells were generated by mitotic recombination. This 20 allowed comparison between the behavior of homozygous mutant clones and their wild-type sister clones, called twin spots, generated during mitotic recombination. Three differences between mutant and wild-type twin clones are obvious: first, *chico* mutant clones are rare: in approximately 90 percent of the clones, only the darkly 25 pigmented wild-type twin spot can be detected. This is most likely due to the fact that small mutant clones encompass only a few ommatidia and escape detection. Secondly, when a non-pigmented mutant clone is detected, the clone is variable in size and often significantly 30 smaller than the wild-type sister clone. Thirdly, there are regional differences in the frequency of mutant clones: clones are more frequently observed in the anterior half of the eye around the equator. The equator defines a line of dorso-ventral mirror image symmetry in 35 the orientation of the ommatidial units. It appears that mutant cells have a better chance to grow or survive in the center of the eye than on its periphery. The behavior

of *chico* mutant clones is similar to that of *M* mutant clones and has been described as cell competition (Morata and Ripoll, 1975; Simpson, 1979). It indicates that the development of *chico* mutant cells is selectively impaired compared with wild-type cells and that there are regional differences in the ability of mutant cells to grow or survive.

In addition, mutant clones in the eye and wing imaginal discs were tested to investigate whether the reduced size of *chico* mutant clones observed in the adult is due to a growth disadvantage or to impaired cell survival during the final stages of differentiation. This investigation was performed on eye imaginal discs containing *chico* mutant or wild-type control clones, marked by the absence of the green *arm-lacZ* staining, and their intensely bright green staining twin spots. As seen in the adult, the mutant clones are smaller than their twin spots and are variable in size. The clones often form a thin line. The fact that *chico* mutant clones in the third instar disc and in the adult eye exhibit a similar behavior argues against the possibility that homozygous mutant *chico* cells are eliminated during differentiation in the pupal stage.

As a critical determinant of organ size through counterbalancing cell proliferation, apoptosis has been postulated (Conlon and Raff, 1999). In order to test whether programmed cell death contributes to size control by reducing cell number, discs containing either *chico* mutant clones or wild-type control clones were analyzed by terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL). No significant difference in occurrence of apoptotic cells between wild-type and mutant clones was detected (data not shown). Since *chico* mutant clones are rather small, mutant clones in a *Minute* background were induced. Even though such clones were greatly enlarged due to their growth advantage they also did not reveal enhanced

apoptosis compared with wild-type control clones in a Minute background (data not shown). Furthermore, no increase in morphological signs of programmed cell death such as enlarged cells or cells with picnotic nuclei in 5 *chico* mutant clones was observed, neither in the imaginal discs nor in the adult eye. These results are also consistent with the FACS analysis of heterozygous and homozygous *chico* mutant wing disc cells. No significant difference in the apoptotic sub-G1 fraction of homozygous 10 *chico* mutant cells compared with heterozygous cells was detected (data not shown). Therefore, these results show that *chico* function is not necessary for cell survival, but is required for cell growth and cell proliferation throughout development. Homozygous *chico* mutant cells 15 have a selective growth disadvantage: they grow more slowly than wild-type cells, as indicated by their under-representation in discs and in the adult eye, and they cannot reach the normal size of wild-type cells. The cell cycle profiles of heterozygous and homozygous *chico* 20 mutant wing disc cells, however, are similar (data not shown) suggesting that the increased cell cycle time of *chico* mutant cells is caused by proportional expansion of the G1, S and G2 phase of the cell cycle.

It was also found that *chico* interacts with 25 other essential compounds. Such compounds with which *chico* genetically interacts are the *Drosophila* insulin receptor and *PI(3)kinase*. Due to the found homology of CHICO with mammalian IRS1-4, genetic interactions with other components involved in signaling via IRS proteins, 30 such as the insulin receptor and the p110 PI3kinase (PI3K), can be studied. Loss of function mutations in *Inr* are lethal but certain heteroallelic combinations survive to adulthood. Such *Inr* mutant flies are reduced in size (Chen et al., 1996). It was found that, like in *chico* 35 mutants, cell size is reduced by 28 percent in *Inr*<sup>313</sup>/*Inr*<sup>327</sup> flies. Furthermore targeted expression of a dominant negative variant of *Drosophila* p110 PI3K in the

developing eye or wing causes a reduction in cell size in the eye, and in both cell size and cell number in the wing. Conversely, overexpression of a constitutively active, membrane-targetted version of PI3K increases cell size and cell number (Leevers et al., 1996). In flies that are homozygous for *chico*, heterozygosity for a hypomorphic *Inr* allele led to a further reduction in cell number in the wing and the eye (see Table 4).

10

15

Table 4: One Mutant Copy of the *Inr* Enhances the Growth Phenotype of *chico* Mutant Cells

Wing Analysis <sup>a</sup>						
Genotype	Area <sup>b,c</sup> (10 <sup>6</sup> µm <sup>2</sup> )	Overall size reduction (%)	Cell density <sup>d</sup> (cells/µm <sup>2</sup> )	Area covered per cell <sup>e</sup> (µm <sup>2</sup> )	Cell size reduction (%)	Approx. No. of cells in measured area <sup>b,f</sup>
<i>chico</i> <sup>2</sup> ; + / +	0.96±0.03	-----	8.0x10 <sup>-3</sup> ±0.12x10 <sup>-3</sup>	125±1.9	-----	7680
<i>chico</i> <sup>2</sup> ; <i>Inr</i> <sup>05545</sup> ; +	0.79±0.03	17.7	7.8x10 <sup>-3</sup> ±0.09x10 <sup>-3</sup>	128±1.5	0	6162
Eye Analysis <sup>g</sup>						
Genotype	Eye area <sup>c</sup>	1	2	3	Area covered per ommatidium <sup>h</sup> (arbitrary units)	
<i>chico</i> <sup>2</sup> ; + / +	261	896±5097	483±7	542		
<i>chico</i> <sup>2</sup> ; <i>Inr</i> <sup>05545</sup> ; +	198	634±3280	411±2	483		

<sup>a</sup> From females four wings of each genotype were analyzed.<sup>b</sup> The area of the whole wing was integrated exclusive the alula and the costal cell.<sup>c</sup> Measured using NIH Image 1.60.<sup>d</sup> Assessed by counting number of wing hairs on the dorsal wing surface in a 10 000 µm<sup>2</sup> area just anterior to the PCV.<sup>e</sup> Reciprocal of column 3.<sup>f</sup> Generated by multiplying the values in column 1 by those in column 3.<sup>g</sup> Eight eyes of each genotype were analyzed.<sup>h</sup> Generated by dividing the values in column 1 by those in column 2.

Thus, in the absence of *chico* function a reduction of the receptor level potentiates the growth reduction. This CHICO independent signaling of INR is 5 likely to be mediated by PI3K binding sites in the C-terminal tail of the INR (Yenush et al., 1996, see discussion). Similarly, expressing a catalytically inactive version of PI3K in *chico* homozygous wing discs leads to a further reduction in wing size by 48 percent 10 (data not shown). Thus the *chico* mutant phenotype is modified by mutations in *Inr* and *PI3K*. This is consistent with the notion that INR, CHICO and PI3K form a conserved signaling pathway involved in the cell autonomous control 15 of growth and cell size in *Drosophila*.

15 Besides of its influence on cell size and cell number, it was found that CHICO also controls lipid levels. This finding is further evidence on the relevance of *chico* in the insulin signalling pathway, since said pathway is known for its role in the control of cellular 20 metabolism in vertebrates and in *C. elegans*. Thus it was investigated whether energy stores are altered in *chico* mutant flies. The fresh and dry weights of different flies were determined (Figure 5A) as well as their 25 amounts of lipid, protein and glycogen per unit of fresh weight (Figure 5B). While there was no significant difference in levels of proteins and glycogen, lipid levels were increased significantly in *chico* males (Figure 5B). In fact, in spite of their smaller size, *chico* males had almost twice as much lipids as wild-type 30 males per mg fresh weight. The dramatic increase in lipids in *chico* mutant males is reminiscent of hypertriglyceridemia in IRS-1 deficient mice (Abe et al., 1998) and of fat accumulation observed in *C. elegans* containing a mutation in the *daf-2* gene, which encodes 35 the insulin receptor homologue (Kimura et al., 1997). Thus it appears that the INR signaling pathway controls cellular metabolism in vertebrates, nematodes and insects.

Since it could be shown that loss of function mutations in *chico*, which encodes a *Drosophila* homolog of IRS 1-4, cause a reduction in overall growth by reducing cell size and cell number, since it could furthermore be

5 shown that the primary function of CHICO is to regulate overall growth by coordinating the control of cell cycle progression and cell growth and not by controlling apoptosis, and since CHICO furthermore is likely to be part of a nutritional sensing system, *chico* and its

10 mutations are very useful tools for the investigation of e.g. the insulin signalling pathway, the screening of potential drugs for the treatment of defects in said pathway, and the screening of drug targets. *Chico* and its mutations are especially suitable tools in *Drosophila*

15 mutants usable as in vitro monitoring systems.

Thus, one subject of the present invention is a method for searching for compounds or mutations interacting directly or indirectly with the insulin signalling pathway, characterized in that a viable insect

20 is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or

25 development time and/or lipid level are detectable in at least part of the animal. In a preferred embodiment said method is a method for searching for compounds or mutations interacting directly or indirectly with CHICO involving life processes, whereby a viable *chico* mutant

30 insect, e.g. a fly such as *Drosophila*, is treated with at least one compound or with at least one compound generating means, and that the effect of such treatment is detected, whereby said mutant comprises at most one wild-type *chico* gene. As already mentioned above, the

35 animals suitable in the scope of the present invention are insects. The advantage of insects is the highly conserved insulin signalling pathway together with their

fast reproducibility. Preferably said method is performed with a *Drosophila* mutant, whereby said mutant is treated in the egg or larvae stadium with said compound or compound generating means. As was shown above, different 5 easily detectable and also quite well quantifiable characteristics can be used to determine the effect of an applied treatment, such as alteration in size and/or weight and/or developmental time and/or lipid levels Of course, for many applications it is desirable that the 10 animals used are already altered in size and/or weight and/or developmental time and/or lipid levels, so that therapeutical effects can be detected.

Mutants suitable for the method of the present invention are such ones that do not comprise a 15 wild-type *chico* gene or that have one wild type *chico* gene. Thus the following combinations are encompassed by the present invention:

- both *chico* genes are totally lost,
- both wild-type *chico* genes are replaced by 20 *chico* alleles with reduced CHICO activity
- both wild-type *chico* genes are replaced by *chico* alleles with no CHICO activity,
- one *chico* gene is totally lacking and one is replaced with a *chico* allele having no CHICO activity,
- one *chico* gene is totally lacking and one 25 is replaced with a *chico* allele having reduced CHICO activity,
- one *chico* allele has no activity and one *chico* allele has reduced activity,
- one *chico* is the wild-type *chico* gene, and 30 the second *chico* is an allele with no activity
- one *chico* is the wild-type *chico* gene, and the second *chico* is an allele with reduced CHICO activity
- one *chico* is the wild-type *chico* gene, and 35 the second *chico* is totally lacking.

As wild-type CHICO in the scope of the present invention any protein is meant that has the same

effect as wild-type CHICO and at least about 50 % identity with the protein structure of Table 1. As wild-type *chico* any *chico* gene is referred to that encodes the amino acid sequence of Table 1 (2, 3), or that encode a 5 protein which is sufficiently homologous to CHICO that it has the same effect in the animals of the present invention as CHICO. Relevant effects of CHICO - as it results from the above disclosure - are cell size, cell number and lipid level. Preferred DNA sequences are e.g. 10 the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. No. 1, 2).

As *chico* mutation according to the present invention any mutation is considered that has an at least reduced activity compared to the activity of the wild 15 type animal. Preferred *chico* mutations are those having no activity and leading to size reduced homozygous animals. Such *chico* mutations are the sequences resulting in a cell number reduction of at least 10 %, preferably at least 30 %, a cell size reduction of at least about 10 20 %, preferably at least about 30 %, and an enhancement of the lipid content per weight unit of at least about 20 %, preferably about 50 % (all % concerning homozygous *chico* mutant animals in comparision with wild-type animals). Preferred examples for such a mutation are the mutations 25 described as *chico*<sup>1</sup> and *chico*<sup>2</sup>.

In general, total loss of *chico* activity is obtained when e.g. at least the PH domain is deleted or tyrosin residues Tyr(411) and Tyr(641) ( positions referred to SEQ ID NOS 2 and 3) are substituted. Partial 30 loss of CHICO activity is e.g. due to substitutions in the region of the PTB domain. The above mentioned alterations in *chico* are by no means complete and have to be clearly understood as non limiting examples.

The animals of the present invention can e.g. 35 be obtained by mutagenesis procedures known to the expert. Suitable mutagens include but are not limited to P-elements, X-ray and ethylmethane sulfonate (EMS).

A suitable method for generating mutant insects comprises that adult insects, in particular males, are treated with a mutation generating means under mutation generating conditions, that thus treated insects 5 are crossed to wild-type or mutant insects, in particular to *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated under suitable conditions.

10 As it has been shown in the scope of the present invention, it is not necessary to generate fully mutant animals. By e.g. the eye-FLP technique, it is possible to selectively generate mutated head regions. Such partially mutated animals are advantageous for many 15 applications, since they avoid the laborious need to generate mutated strains.

Specific and much preferred applications of the animals and the method of the present invention are the screening for compounds that are useful in the 20 modulation, e.g. the treatment, of diabetes type 2, and the further investigation of diabetes type 2, in particular the search for further factors involved in the development of said disease. Such factors possibly involved in the development of said (but also other) 25 disease can be found by applying a mutation generating means, in particular a mutagen such as radiation, P element, or chemical compound, to the animal under conditions suitable to generate gene defects in the factors

30 One very interesting application of *chico* mutant insects or insects with *chico* phenotype is connected with the fact that the insulin signaling pathway is conserved in structure and function. In mammalian cells, activation of the insulin or IGF-1 35 (insulin-like-growth factor-1) receptor by insulin and IGF-1, respectively, results in the recruitment of IRS-1 or IRS-2 to the receptor via interaction of the IRS PTB

domains with a phosphotyrosine motif (NPXY) in the juxtamembrane region of the receptors. Phosphorylation of multiple tyrosine residues of IRS-1 triggers the activation of various signaling pathways including the 5 RAS/MAP kinase pathway via the SH2/S3 adaptor GRB2, and the PI3K/PKB pathway via the p85 SH2 adaptor subunit of p110 PI3K (Yenush and White, 1997). The *Drosophila* INR shares many structural features with its human homologues, including its heterotetrameric structure and 10 a conserved PTB consensus binding site in the juxtamembrane region. Although, the *Drosophila* INR contains a 400 amino acid C-terminal extension not found in any of the vertebrate receptors, it is nevertheless an important tool not only for screening compounds 15 activating the insulin signalling pathway, but also for finding and/or further investigating compounds that are also members of said pathway. However, also the C terminal extension is of importance. This C-terminal tail contains three YXXM consensus binding sites for the SH2 20 domain of the p60 subunit of PI3K and four additional NPXY consensus PTB binding sites. The C-terminal domain is functional, since expression of a chimeric receptor consisting of the extracellular domain of the human INR and the intracellular domain of the *Drosophila* INR in 25 murine 32D cells lacking endogenous IRS-1 can partially activate mammalian PI3K and S6K. In contrast, the ability of the human INR to activate PI3K in this system is strictly dependent on the coexpression of IRS-1 (Yenush et al., 1996). These findings and the identification of 30 CHICO suggest that in e.g. *Drosophila* INR couples to the downstream effector PI3K in two different ways, one using docking sites in the INR C-terminal tail and the other connecting through docking sites in CHICO.

As described here, the effects on growth and 35 cell size of *chico* mutants are remarkably similar to the phenotypes of mutations in genes encoding other components of the INR pathway in e.g. *Drosophila*.

Although loss of function mutations in the *Drosophila INR* gene are lethal, certain heteroallelic combinations are viable and show delayed development, reduced body size and decreased cell number (Chen et al., 1996) and cell size (this application). Expression of dominant negative or constitutively active variants of p110 PI3K in the developing wing and eye reduces or increases cell number and cell size, respectively (Leevers et al., 1996). Furthermore viable mutations in the gene encoding *Drosophila Protein Kinase B* (Staveley et al., 1998) cause a reduction in cell number and cell size (H.S. and E.H., unpublished results). The striking similarities between the phenotypes of *chico* and mutations in the genes encoding *INR* and *DPKB*, as well as the genetic interactions between mutations in *Inr*, *chico* and *PI3K*, show the specific role of the *INR* pathway in control of cell growth and cell number as a process independent of pattern formation and makes not only flies with a *chico* mutation induced phenotype a valuable *in vivo* monitoring system, but also flies with a *chico* mutation and at least one further mutation as described above.

Thus, the *chico* mutant animals of the present invention are an especially useful tool to investigate the insulin signaling pathway and possible pharmaceuticals to overcome defects therein, since said pathway is highly conserved from vertebrates to *Drosophila*, not only in regard to its structure but also to its function.

30

#### Examples

**Example 1: Drosophila strains**  
*chico*<sup>1</sup> is a P element insertion allele, originally called *fs(2)4*<sup>1</sup> (Berg and Spradling, 1991). The P element was mapped using standard PCR with primers specific to the 3' end of the P element and to the

genomic sequence. Subsequently, the insertion site was precisely determined by sequencing the amplified PCR fragment. *chico*<sup>2</sup> was derived from *chico*<sup>1</sup> by mobilizing the P element. The resulting *Df(2L)f1p147E* deletes the 5 translation start site and the regulatory region of *chico* and the 3' coding sequences of *bsk*. The *bsk* mutation was complemented by insertion of a *bsk* rescue construct on the *Df(2L)f1p147E* chromosome (Riesgo et al. 1996). For 10 genetic interaction analysis we used *Dp110*<sup>D954A</sup>, a dominant negative form of *p110* of *Drosophila PI3K* (Leevers et al., 1996) and *Inr*<sup>05545</sup>, a P element induced hypomorphic allele (Fernandez et al., 1995). The *Dp110*<sup>D954A</sup> transgene was driven by GAL4 which was expressed in the dorsal wing pouch using the MS-1096 line (Capdevila and Guerrero, 15 1994). The *Inr* allele is hypomorphic and recessive lethal.

**Example 2: Molecular characterization of *chico***

20 An 11 kb genomic DNA fragment which has been described in Riesgo-Escobar et al., 1996 and encompasses the Jun kinase (*bsk*) and *chico* transcription units was used to screen a *Drosophila* cDNA library. From this screen, a partial cDNA (U1) for *chico* was recovered, 25 sequenced, and used to screen an embryonic *Drosophila* cDNA library. Several cDNAs were isolated and partially sequenced (U2-U4). Sequence search of the *Drosophila* EST database with these sequences identified the EST GH02661. Sequencing of this EST clone indicated that it represents 30 a full-length *chico* transcript that contains a consensus sequence for translation initiation (Cavener, 1987) and ends with a poly A tail 15 bp after a consensus poly-A addition signal. All cDNAs were found to encode the same transcript. The 11 kb genomic region was fully sequenced 35 to establish the exon/intron structure of *chico*, and also its position in relation to *bsk* and *ME31B*. From a genomic phage of the region, a BamHI/ BamHI fragment was

subcloned into pBluescript, and a resection from the *bsk* side was performed to generate a 9.5 kb fragment that was subcloned into a transformation vector and used to generate a genomic rescue construct for *chico*. pWAX 5 (described in Riesgo-Escovar et al., 1996) rescued both the phenotypes of *chico* and *bsk* separately and in a double mutant (data not shown, and Riesgo-Escovar et al., 1996).

10 **Example 3: Weight Analysis**

Body weight of individual male and female flies (n = 20) was measured with a precision scale (range 0.001 - 10 mg; Mettler ME30). Flies were reared under the same growth conditions and were age-matched (two days 15 old) before weighing. The genotypes analyzed were the following: *y w*; *+/+*, *y w*; *chico*<sup>2</sup>*/+* (heterozygotes for the synthetic null allele), *y w*; *chico*<sup>2</sup>/*chico*<sup>2</sup>, *y w*; *chico*<sup>1</sup>*/+* (heterozygotes for the P element insertion allele), *y w*; *chico*<sup>1</sup>/*chico*<sup>1</sup> and *y w*; *chico*<sup>1</sup>/*chico*<sup>2</sup>.

20 **Example 4: Clonal Analysis**

*chico*<sup>1</sup> was recombined onto the FRT40 chromosome (Xu and Rubin, 1993).

25 Germline clones of the *chico*<sup>1</sup> allele were generated using the autosomal dominant female-sterile technique in combination with the Flp recombinase system (Chou and Perrimon, 1996). Females of the genotype *y w*; *chico*<sup>1</sup>, FRT40/CyO *y*<sup>+</sup> were crossed with *y w hsFlp/Y*; *P(ovo*<sup>D1</sup> *w*<sup>+</sup>) FRT40/CyO males. Early third instar larvae 30 were heat-shocked for 1.5 hr at 38°C. Females of the genotype *y w hsFlp/y w*; *chico*<sup>1</sup> FRT40/*P(ovo*<sup>D1</sup> *w*<sup>+</sup>) FRT40 were selected and crossed to *chico*<sup>1</sup>/CyO *y*<sup>+</sup> males. The resulting progeny lacking any zygotic *chico* function and their siblings bearing the CyO *y*<sup>+</sup> chromosome were 35 analyzed.

For the generation of clones in the adult eye larvae of the genotype *y w hsFlp*; *chico*<sup>1</sup> FRT40/ *w*<sup>+</sup> FRT40

were subjected to a heat shock 24 - 48 hr AED for 1 hr at 37°C to induce mitotic recombination. Adults were examined for *w* clones and their corresponding twin spots (red pigmented) in the eye. Histological sections of the 5 eyes were done as described previously (Basler and Hafen, 1988). Selective removal of *chico* function in the eye disc progenitors was achieved in animals of the genotype *y w ey-Flp; chico<sup>1</sup> FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40* and *y w ey-Flp; chico<sup>1</sup> FRT40 / P(w<sup>+</sup>) 1(2)2L-3.1 FRT40; P(w<sup>+</sup> chico 10 genomic rescue construct pCSR4)/+*. The *eyFlp* technique has been developed by B. Dickson (personal communication).

Wing clones. Larvae of the genotype *f hsFlp/f; chico<sup>1</sup> FRT40/ck P(f<sup>+</sup>) FRT40* were subjected to a 15 heat shock 48 - 72 hr AED for 0.5 hr at 36°C to induce mitotic recombination. Wings were mounted and examined under a compound microscope.

Disc clones. Larvae of the genotype *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) FRT40*, respectively were 20 subjected to a heat shock 24 -48 hr AED for 0.5 hr at 32°C to induce mitotic recombination at a low frequency. Larvae at late third instar stage were dissected. Discs were fixed and permeabilized and stained with appropriate 25 antibodies. Antibodies were: rabbit anti- $\beta$ -Gal (1/2000) and FITC- or TR-conjugated secondary antibodies (1/200). Actin filaments were stained using phalloidin-TR (Molecular Probes).

30

#### Example 5: TUNEL Assay

Apoptotic cells were detected using the ApopTag system (ONCOR). Clones in larvae of the genotype *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) FRT40*, respectively, and 35 *y w hsFlp/y w; chico<sup>1</sup> FRT40/P(arm-lacZ w<sup>+</sup>) M(2L)Z FRT 40* and *y w hsFlp/y w; FRT40/P(arm-lacZ w<sup>+</sup>) M(2L)Z FRT40*, respectively, were induced as described above. Larvae at

late third instar stage were dissected. Discs were fixed and stained as described above. 3'-OH ends of DNA were labelled for 0.5 hr at 37°C by addition of digoxigenin 11-UTPs by the enzyme TdT and subsequently detected with 5 FITC-conjugated anti-digoxigenin antibody. Discs of *GMR-grim* larvae, kindly provided by John Abrams (University of Texas), were used as positive controls.

**Example 6: Flow Cytometry**

10 Female larvae of the genotype *chico*<sup>2</sup>/+ and *chico*<sup>2</sup>/*chico*<sup>2</sup>, respectively, were dissected at late third instar stage (non-wandering stage). Dissociation of wing discs was done as described in Neufeld et al., 1998. Approximately 20 discs were dissociated. The cell 15 suspension was analyzed using a Becton Dickinson FACStar<sup>Plus</sup> and the data was analyzed using Cell Quest (Becton Dickinson).

**Example 7: Metabolic Studies**

20 Adult males (n = 10) of the genotypes *chico*<sup>2</sup>/*chico*<sup>2</sup>, *chico*<sup>2</sup>/+ and +/+ were collected 3 days after eclosion. The fresh and dry weight, respectively, from individual males was determined. To determine the dry weight, males were fixed in 100% ethanol for 10 25 minutes at 90°C and then dried for 2 hr at 110°C. Protein data were obtained through Kjeldahl digestion and subsequent Nesslerization (Minari and Zliversmit, 1963), with total nitrogen converted to protein by using a factor of 6.25. Glycogen and lipid data were obtained as 30 described in van Handel and Day, 1988.

While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited 35 thereto but may be otherwise variously embodied and practiced within the scope of the following claims.

Literature

5 Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M.,  
Osuga, J., Shionoiri, F., Yahagi, N., Kadokawa, T.,  
Tamekoto, H., Ishibashi, S., Yazaki, Y., and Makuuchi, M.  
(1998). Hypertension, hypertriglyceridemia, and impaired  
endothelium-dependent vascular relaxation in mice lacking  
insulin receptor substrate-1. *J. Clin. Invest.* 101, 1784-  
1788.

10 Basler, K. and Hafen, E. (1988). Control of  
photoreceptor cell fate by the sevenless protein requires  
a functional tyrosine kinase domain. *Cell* 54, 299-312.

15 Berg, C. A. and Spradling, A. C. (1991). Studies on the  
rate and site-specificity of P-element transposition.  
*Genetics* 127, 515-524.

20 Bryant, P. J. and Simpson, P. (1984). Intrinsic and  
extrinsic control of growth in developing organs.  
*Quarterly Review of Biology* 59, 387-415.

25 Capdevila, J. and Guerrero, I. (1994). Targeted  
expression of the signaling molecule decapentaplegic  
induces pattern duplications and growth alterations in  
*Drosophila* wings. *EMBO J.* 13, 4459-4468.

30 Cavener, D. R. (1987). Comparison of the consensus  
sequence flanking translational start sites in *Drosophila*  
and vertebrates. *Nucl. Acids Res.* 15, 1353-1361.

35 Chen, C., Jack, J., and Garofalo, R. S. (1996). The  
*Drosophila* insulin receptor is required for normal  
growth. *Endocrinology* 137, 846-856.

40 Chou, T. B. and Perrimon, N. (1996). The autosomal FLP-  
DFS technique for generating germline mosaics in  
*Drosophila melanogaster*. *Genetics* 144, 1673-1679.

45 Conlon, I. and Raff, M. (1999). Size control in animal  
development. *Cell* 96, 235-244.

de Valoir, T., Tucker, M. A., Belikoff, E. J., Camp, L.  
A., Bolduc, C., and Beckingham, K. (1991). A second  
maternally expressed *Drosophila* gene encodes a putative  
RNA helicase of the "DEAD box" family. *Proc. Natl. Acad.  
Sci. USA* 88, 2113-2117.

Edgar, B. A., Lehman, D. A., and O'Farrell, P. H. (1994). Transcriptional regulation of string (cdc25): A link between developmental programming and the cell cycle.  
5 Development 120, 3131-3143.

Fernandez, R., Tabarini, D., Azpiazu, N., Frasch, M., and Schlessinger, J. (1995). The Drosophila insulin receptor homolog: a gene essential for embryonic development  
10 encodes two receptor isoforms with different signaling potential. EMBO J. 14, 3373-3384.

Gallant, P., Shiio, Y., Cheng, P. F., Parkhurst, S. M., and Eisenman, R. N. (1996). Myc and Max homologs in  
15 Drosophila. Science 274, 1523-1527.

Kimura, K. D., Tissenbaum, H. A., Liu, Y., and Ruvkun, G. (1997). daf-2, an insulin receptor-like gene that regulates longevity and diapause in *Caenorhabditis elegans*. Science 277, 942-946.  
20

Leevers, S. J., Weinkove, D., MacDougall, L. K., Hafen, E., and Waterfield, M. D. (1996). The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth.  
25 EMBO J. 15, 6584-6594.

Minari, O. and Zliversmit, D. B. (1963). Use of KCN for stabilization of color in direct Nesslerization of Kjeldahl digests. Anal. Biochem. 6, 320-327.  
30

Morata, G. and Ripoll, P. (1975). Minutes: Mutants of Drosophila autonomously affecting cell division rate. Dev. Biol. 42, 211-221.

35 Neufeld, T. P., Delacruz, A. F. A., Johnston, L. A., and Edgar, B. A. (1998). Coordination of Growth and Cell Division in the Drosophila Wing. Cell 93, 1183-1193.

Olivier, J. P., Raabe, T., Henkemeyer, M., Dickson, B.,  
40 Mbamalu, G., Margolis, B., Schlessinger, J., Hafen, E., and Pawson, T. (1993). A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell 73, 179-191.

45 Quiring, R., Walldorf, U., Kloter, U., and Gehring, W. J. (1994). Homology of the eyeless gene of Drosophila to the Small eye gene in mice and Aniridia in humans. Science 265, 785-789.

Riddle, D. L. (1988). The dauer larva. In *The nematode Caenorhabditis elegans*, W. N. Wood, ed. (Cold Spring Harbor: Cold Spring Harbor Laboratory Press) 393-412.

5 Riesgo-Escovar, J. R., Jenni, M., Fritz, A., and Hafen, E. (1996). The *Drosophila* Jun-N-terminal kinase is required for cell morphogenesis but not for DJun-dependent cell fate specification in the eye. *Genes Dev.* 10, 2759-2768.

10 Robertson, F. W. (1963). The ecological genetics of growth in *Drosophila*. VI. The genetic correlation between the duration of the larval period and body size in relation to larval diet. 4, 74-92.

15 Santamaria, P. (1983). Analysis of haploid mosaics in *Drosophila*. *Dev. Biol.* 96, 285-295.

20 Simpson, P. (1979). Parameters of cell competition in the compartments of the wing disc of *Drosophila*. *Dev. Biol.* 69, 182-193.

25 Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993). SH2 domains recognize specific phosphopeptide sequences. *Cell* 72, 767-778.

30 Staveley, B. E., Ruel, L., Jin, J., Stambolic, V., Mastronardi, F. G., Heitzler, P., Woodgett, J. R., and Manoukian, A. S. (1998). Genetic analysis of protein kinase B (AKT) in *Drosophila*. *Curr. Biol.* 8, 599-602.

35 Stewart, C. E. and Rotwein, P. (1996). Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. *Physiological Reviews* 76, 1005-1026.

40 Thomas, G. and Hall, M. N. (1997). TOR signalling and control of cell growth. *Curr. Opin. Cell Biol.* 9, 782-787.

45 van Handel, E. and Day, J. F. (1988). Assay of lipids, glycogen and sugars in individual mosquitoes: correlations with wing length in field-collected *Aedes vexans*. *J. Amer. Mosq. Contr. Assoc.* 4, 549-550.

Weigmann, K., Cohen, S. M., and Lehner, C. F. (1997). Cell cycle progression, growth and patterning in imaginal discs despite inhibition of cell division after inactivation of *Drosophila* Cdc2 kinase. *Development* 124, 5 3555-3563.

Weinkove, D., Leevers, S. J., MacDougall, L. K., and Waterfield, M. D. (1997). p60 is an adaptor for the *Drosophila* phosphoinositide 3-kinase, Dp110. *J. Biol. Chem.* 272, 14606-14610.

Xu, T. and Rubin, G. M. (1993). Analysis of genetic mosaics in developing and adult *Drosophila* tissues. *Development* 117, 1223-1237.

Yenush, L., Fernandez, R., Myers, M. G., Jr., Grammer, T. C., Sun, X. J., Blenis, J., Pierce, J. H., Schlessinger, J., and White, M. F. (1996). The *Drosophila* insulin receptor activates multiple signalling pathways but requires insulin receptor substrate proteins for DNA synthesis. *Mol. Cell. Biol.* 16, 2509-2517.

Yenush, L. and White, M. F. (1997). The IRS-signalling system during insulin and cytokine action. *Bioessays* 19, 25 491-500.

10/019098

531 Rec'd PCT/.. 20 DEC 2001

Claims

1. A method for searching for compounds or mutations interacting directly or indirectly with the insulin signaling pathway, characterized in that a viable chico mutant insect is treated with at least one compound or with at least one mutation generating means, and that the effect of such treatment on the body size and/or cell size and/or development time and/or lipid level is determined whereby alterations of the body size and/or cell size and/or development time and/or lipid level are detectable in at least part of the animal.
2. The method of claim 1 characterized in that the viable chico mutant insect comprises at most one wild-type *chico* gene.
3. The method of claim 2 wherein the mutant is a *Drosophila* mutant and wherein said mutant is treated in the egg or larvae stadium with said compound or compound generating means.
- 20 4. The method of claim 2 or 3 wherein the mutant does not comprise a wild-type *chico* gene.
5. The method of claim 2 or 3 wherein the *Drosophila* mutant comprises one wild-type *chico* gene.
- 25 6. The method of claim 5 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).
7. The method of claim 6, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 1 (SEQ. ID. NO. 1, 2) or Table 2 (SEQ. ID. NO. 4).
- 30 8. The method of anyone of claims 2 to 7 wherein the *Drosophila* mutant comprises at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.
- 35 9. The method of claim 7 wherein the *chico* mutation is the mutation described in Figure 3A.

10. The method of anyone of claims 2 to 9 wherein the *Drosophila* lacks at least one *chico* gene.

11. The method of claim 10 wherein the mutant lacks both *chico* genes.

5 12. The method of anyone of claims 1 to 11 wherein the compound is a compound for the treatment of diabetes type 2.

10 13. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level 10 is detectable in the whole animal.

15 14. The method of anyone of claims 1 to 12, wherein the alteration of the body size and/or the cell size and/or the development time and/or the lipid level 15 is detectable in the head region only.

20 15. A viable insect mutant comprising at most one wild-type *chico* gene in at least a part of its body and said at least one part of the body shows reduced size.

25 16. The mutant of claim 15 that does not comprise as sole *chico* genes two *chico*<sup>1</sup> genes.

17. The mutant of claim 15 or 16 that does not comprise a wild-type *chico* gene.

25 18. The mutant of claim 15 or 16 that comprises one wild-type *chico* gene.

19. The mutant of claim 18 wherein the wild-type *chico* gene encodes the amino acid sequence of Table 1 (SEQ. ID. NO. 2, 3).

30 20. The mutant of claim 19, wherein the wild-type *chico* gene is the genomic or the cDNA sequence represented in Table 2 (SEQ. ID. NO. 4) or Table 1 (SEQ. ID. NO. 1, 2).

35 21. The mutant of anyone of claims 15 to 20 comprising at least one *chico* mutation with lacking or reduced activity compared to wild-type *chico*.

22. The mutant of claim 21 wherein the *chico* mutation is the mutation described in Figure 3A.

23. The mutant of anyone of claims 15 to 22 lacking at least one *chico* gene.

24. The mutant of claim 15 lacking both *chico* genes.

5 25. The mutant of anyone of claims 15 to 24 which is a fly mutant, in particular a *Drosophila* mutant.

26. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the whole body of the insect.

10 27. The mutant of anyone of claims 15 to 25, wherein at most one wild-type *chico* gene is found in the head region of the insect only.

15 28. Use of an insect according to anyone of claims 15 to 27 as a means in screening compounds for modulating diseases.

29. Use of an insect according to anyone of claims 15 to 27 as a means for searching for mutations involved directly or indirectly in the insulin signaling pathway.

20 30. Use according to claim 22 or 23, characterized in that the disease is diabetes type 2.


31. A method for generating a mutant insect, characterized in that adult animals, in particular males, are treated with a mutation generating means under 25 mutation generating conditions, that thus treated insects are crossed to wild-type or mutant insects, in particular *chico* mutant insects, and that viable offsprings with altered cell number and /or cell size and/or developmental time and/or lipid levels are cultivated 30 under suitable conditions.

10/019098

PCT/IB99/01166

WO 00/78940

1/9



**Figure 1A**




Figure 1B




Figure 2A




Figure 2B




Figure 2C




Figure 3A

MASISDDGMALSGYLLKTMKKFFVLYEETSTSAARLEYDTEKKFLQRAEPKRVVIYLKNCFN  
INRRLDTKHREVVIVLSSRDOGFGIVLENENDLRKWLDKLLVILQRNIANSNGTAHSPYDHWQVVIT  
OKKGISEKVGITGTYHCCCLTSKSLTFVCIGPEKTPNGEDRVASIEIILTTIRRCGHASPOCIFYV  
ELGRQSVLGSGLIWMETDNAIAATNMHNTILSAMSAKTESNTNLINVYQNRPDLSHEPMRKRSS  
ANEASKPINVNVIQNSLNRSCSSPHNYGFGRCRCDSLPTRNGTLLSESSNQTYFGSNHGLRS  
NTISGIRPHSTNKHNSNSPTFTMPPLRCSESESSISVDESDNGSFSHYRLNTRSSSETAIPPEENID  
DFASAELEFSKVTEQNVSDENYIPMNPVNPTDAIHEKEKADMQRLEDASLHENFPEHASEKLIKDF  
DLDSDNQCCRPIRAYSIGNKVEHILKFNKRLGHLNDTGQNPNRVRAYSVGSKSKIPRCDLQRVVLV  
EDNKHEFTANRSQSSITKEGTSYGSSANRQKKSTSAPLLSLKNQINSDRMSDLMEIDFSQATNLE  
KOKFIKNEIPKYIENVFPKAPRTDSSSLHATSQKDIFNGTKLNNTAITSEDGYLEMKPVGNG  
YTPSSNCLPMKVERLKLSDYQTAPPITATAAPVHDLNKISTYNTNISAEKWREQPSRSEEKKNSPL  
NDNTFGLKPTNVESTSKSHDVHSANQIDSEKVAQSSDKLNNLADKIVENNNDIGHEEKKLVH  
SISSEDYTQIKDKSNDFTKNEAGYKILQIKSDSSLISSKLYQKGIIHKDNLERSQRLTESVNTIP  
DNATAVSSSSILTKENINSAKPAAADSRSTGTDPSQNLQIKDLNFPSSRSSRISQPELHY  
ASLDLPHCSGQNPAYKLRGSRESPPVSACPEDGNTYAKIDFDQSDSSSSNIFNTZ


## Figure 3B

6/9

CHICOPH	1	• • • • •	M A L S G Y L K K L K T . . . . .	M K K K F F V L . . . . .	Y E E T S T S A A R L E Y Y . . . . .
IRS1PH	1	• • • • •	M A S P P D T D G F S D V R K V G Y L R K P K S . . . . .	M H K R F F V L R A . . . . .	A S E A G G . . . . .
IRS2PH	1	• • • • •	S V R K C G Y L R K O K H . . . . .	G H K R F F V L R G P G T G G D E A S A A G G S P P Q . . . . .	P A R L E Y Y . . . . .
IRS3PH	1	• • • • •	D V R L C G H L R K O K S Q F T R R R F F V L R A . . . . .	D P P R L E C Y . . . . .	D P P R L E C Y . . . . .
IRS4PH	1	• • • • •	E V U C K R G Y L R K O K H . . . . .	G H R R Y E V L K L . . . . .	E T A D A P A R L E Y Y . . . . .
consensus			V R K G Y L F K Q K T . . . . .	H K F F V L R . . . . .	P A R L E Y Y . . . . .
CHICOPH	35	D T E K K F L Q R A . . . . .	D S K R V I Y L K N C F N I N R R L D T K H R F V I V L S . . . . .		
IRS1PH	48	E N E K K A . . . . .	P K R S I P L E S S C F N I N K R A D S K N K H E V A L . . . . .		
IRS2PH	48	E S E K K A . . . . .	P K R V I A L D C C L N I N K R A D A K H K Y L I A L . . . . .		
IRS3PH	34	E S E K F L A S G C R P P R . . . . .	P R R T V S L E G A C T I S K R A D A R Q R H L I V I F T . . . . .		
IRS4PH	36	E N A R K E . . . . .	P R R V I T L Y Q C F S V S O R A D A R Y R H L I A L . . . . .		
consensus		e k k t	P K R V I L e c r n i n R a d a k r h l i a l		
CHICOPH	74	S R D G G G F G I V L E N E N D L R K W L D K I L L V E . . . . .			
IRS1PH	87	Y T R D E H F A I A A D S E A E Q D S W Y Q A L L Q E H N R . . . . .			
IRS2PH	87	Y T K D E X F A V A A E N E Q E Q E G W Y R A L T D L . . . . .			
IRS3PH	78	Y T S D S S L G V A A A S E A E Q Q T W Y S A L L E V . . . . .			
IRS4PH	94	F T Q D E Y F A M V A E N E S E Q E S W Y L L S R E . . . . .			
consensus		y t d e f a a a e n e e q	W Y a l l I		
CHICO PTB	1	D H V W . . . . .	Q V V V I Q K K G I S E K V G I . . . . .		
IRS1PTB	1	F K E V W . . . . .	Q V I L K P K G L G Q T K N L . . . . .		
IRS2PTB	1	Y R E V W . . . . .	Q V N L K P K G L G Q S K N L . . . . .		
IRS3PTB	1	F Q D V W F T P V T I L R S K G L G R A P G L S S G S Y R L C L G S G A L S S L I R K P G S R D S R A T P P P V I R L . . . . .			
IRS4PTB	1	Y K D V W . . . . .	Q V I V K P R G L H R K E L . . . . .		
consensus		V W q v v 1 k p k g 1 g	K 1 e y r i c l t s		
CHICO PTB	53	L I L T T I R R C G H A S P Q C I F I V E L G R O S V U L G S G D I L W E T D N A A I A T N M H N T I L S A M . . . . .			
IRS1PTB	48	O I M N I R R C G H S . . . . .	E N F F I E V G R S A V T G P G E E F W Q V D D S V V A Q N M H E T I L E A M R R M . . . . .		
IRS2PTB	48	O I M N I R R C G H S . . . . .	O S F F I E V G R S A V T G P G E L W Q A D D S V V A Q N I H E T I L E A M K A L . . . . .		
IRS3PTB	61	S I L S V R R C G H A . . . . .	D S F F F I E L G R S A P I G P G E L W Q A P D A V V A Q S I H E T V L A M K R L . . . . .		
IRS4PTB	48	O I L S I R R C G H S . . . . .	E Q Y F F I E V G R S T E V I G P G E L W Q D D C V V A Q N H E L F E K A R A L . . . . .		
consensus		q 1 I R R C G H S . . . . .	f f f I V G R S A V G P G e l w m q d d v v A q n m H e t i l e a M r a l		

Figure 3C

7/9



**Figure 4A**



**Figure 4B**



**Figure 4C**





Figure 5A



## DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "**IN VIVO INSECT MODEL SYSTEM FOR TYPE-2 DIABETES**," the specification of which (check one):  is attached hereto;  was filed on December 20, 2001 as Application Serial No. 10/019,098;  was filed as PCT International Application No. PCT/IB99/01166 on June 22, 1999. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

			Priority Claimed
(Application Serial Number)	(Country)	(Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:			
(Application Serial Number)		(Day/Month/Year Filed)	
(Application Serial Number)		(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PCT/IB99/01166 (Application Serial Number)	June 22, 1999 (Day/Month/Year Filed)	Pending (Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

## APPLICABLE RULES AND STATUTES

### 37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

### 35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

### 35 U.S.C. 103. CONDITIONS FOR PATENTABILITY; NON-OBVIOUS SUBJECT MATTER (Applicable Portion)

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

### 35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

28  
John B. Lungmus (18,566)  
Allen H. Gerstein (22,218)  
Nate F. Scarpelli (22,320)  
Michael F. Borun (25,447)  
Carl E. Moore, Jr. (26,487)  
Richard H. Anderson (26,526)  
Patrick D. Ertel (26,877)


Richard B. Hoffman (26,910)  
James P. Zeller (28,491)  
Kevin D. Hogg (31,839)  
Jeffrey S. Sharp (31,879)  
Martin J. Hirsch (32,237)  
Richard M. La Barge (32,254)  
James J. Napoli (32,361)

Robert M. Gerstein (34,824)  
Michael R. Hull (35,902)  
Anthony G. Sitko (36,278)  
James A. Flight (37,622)  
Roger A. Heppermann (37,641)  
David A. Gass (38,153)  
Gregory C. Mayer (38,238)

Michael R. Weiner (38,359)  
David C. Read (39,811)  
Thomas A. Miller (40,091)  
William K. Merkel (40,725)  
Sandip H. Patel (43,848)  
Kevin M. Flowers (44,684)  
William J. Kramer (46,229)

Send correspondence to: Jeffrey S. Sharp

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
<u>Marshall, Gerstein &amp; Borun</u>	312-474-6300	<u>6300 Sears Tower</u> <u>233 South Wacker Drive</u>	<u>Chicago, Illinois</u>	<u>60606-6357</u>

Full Name of First or Sole Inventor <u>Ernst Hafen</u>	Citizenship Swiss
Residence Address - Street Zoologisches Institut/Winterthurerstrasse 190	Post Office Address - Street Zoologisches Institut/Winterthurerstrasse 190
City (Zip) CH-8057 Zürich	City (Zip) CH-8057 Zürich
State or Country Switzerland	State or Country Switzerland
Date <input checked="" type="checkbox"/> 13.03.02	Signature 

## SEQUENCE LISTING

<110> Universitaet Zuerich

<120> In vivo model system for type-2 diabetes

<130> Universitaet Zuerich

<140>

<141>

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2907

<212> DNA

<213> *Drosophila melanogaster*

<400> 1

atggcatcaa tatcggatga cggcatggcg ctgagtggt acctcaagaa gctgaagacc 60

atgaagaaga agttctttgt gctgtacgag gagacgagca cttcggcagc ccggctggag 120

tactacgata ccgaaaagaa gttcctgcaa agagccgagc caaaaagggt tatatatctg 180

aagaattgct tcaacatcaa tcgccgtttg gacaccaagc atagatttgcatttgctc 240

tcctccagag acgggtggatt cggcatcggt ctcgagaacg aaaatgattt acgcaaatgg 300

ttggacaaac tactagttct acaaaggaac atagccaatt cgaatggAAC agcgcactca 360

ccttatgacc acgtttggca agttgtcatt caaaaagggt gtatttcgga gaaagttgga 420

atcaccggaa cctaccactg ttgccttact tcaaaatccc tgacattcgt gtgcattgga 480

ccggagaaga cgcccaatgg cgaggatcgc gttgcgagca ttgaaatact tttgaccacg 540

atcaggcgat gcggtcatgc atccccacaa tgtatattct acgtggact tggccgccaa 600

agtgtcttgg gatctgggtga tctgtggatg gagacggata acgcagctat tgctactaat 660

atgcacaaca cgataactgag cgctatgtca gccaaaacag agtcgaacac gaatttaata 720

aacgtttatc agaatacgacc tgacttaagt cacgagccca tgagaaagcg atcgtcgtct 780

gcaaacgaag catcgaagcc gataaacgtta aatgtcatac aaaatagtca aaactctctc 840

gaatttgcgca gctgcagttc gccccataac tatggtttcg gcagagagag atgcgatagc 900  
ttaccaacca gaaatggaac cctaagcgag tccagcaatc aaacgtactt tggttccaac 960  
catggactgc gatccaatac tatatctggc atccgtccgc actcaaccaa caagcatagt 1020  
aatagtccaa cgttcaccat gccattaaga tgctcagaat ccgaagagtc atcaattagt 1080  
gtcgatgaat ccgacgacaa cggcagttt agccactaca gattaaacac gcggtcatct 1140  
gagacggcaa ttccctgagga aaacattgat gactttgcca gtgcggaatt attagcaaa 1200  
gtcaccgaac aaaatgtaaag tgacgaaaac tacataccga tgaatccagt caatcctacc 1260  
gatgctatcc atgaaaagga gaaggctgat atgcagagat tggaaagatgc ttgcgtgcat 1320  
ttcaactttc cggagcacgc gtcggaaaag cttgctaagg attttgcattt ggactctgat 1380  
aaccaatgct gtcgtcccat tcgcgcctat tcgataggca acaaggttga gcatttaaag 1440  
ttaataagc gcctgggaca cttgaatgat acgggacaga atccgaatcg cgtgcgagcc 1500  
tactcggttg gctccaaatc gaagataccg cgctgcgacc tgcagcgagt ggtcctcggt 1560  
gaggacaata aacatgagtt cacagcgaat aggagtcaga gtagcattac caaggaagga 1620  
accagctatg gcagcagtgc caatcgacaa aagaagtcca caagtgcctcc actcctcagt 1680  
ctgaagaacc agataaaactc cgaccgaatg agtgacttaa tggaaattga ttttcacaa 1740  
gcaaccaatt tgaaaagca gaagttcatc aagaataatg aaattccgaa atacattgaa 1800  
aacgtgttcc caaaagcccc gcgaacggat agctccagcc taactctgca cgccacaagt 1860  
caaaaggaca ttttcaatgg caccaaacta aataacactg cgatcacatc cgaggatgg 1920  
tacctcgaga tgaagccagt cggtaatgga tacactcccc gttcgaatttgc cctgccaatg 1980  
aaagtggaga aactcaagct atccgactat cagacagcac cgccactcac cgcaacagcc 2040  
gcaccagtgc acgatttaaa caaaatttgc acatacaata tatccgtga gaaatggaga 2100  
gaacagcccc gcagaagcga ggaaaagaag tcgaactcgc cattgaatga caacacctt 2160  
agctcgaaac ccacaaatgt cgagagtaca agcaaaagcc atgatgttca ttccagcaat 2220  
caaatttgc gcgagaaaagt gtgcgcgcag agcagcgata agctaaataa tcatctggcc 2280

gacaagattg tcgagaacaa caatttggat ataggcgggc atgagggaaa gaagttggtt 2340  
 cattcgataa gcagcgaaga ctacacacaa atcaaggaca aatcgaatga tttcacaaaa 2400  
 tttaacgaag ccggctacaa aattctgcaa attaaaagcg acagctcact catctcatcg 2460  
 aagctataacc aaaagggtat acacaaggat aacttggagc gttcgagcacttacagag 2520  
 agtgtgaata cgattcccga taatgccacc gccaccgcgg tgagcagcag ctcactcacc 2580  
 aaattcaata taaattcagc aaagccagcc gccggccggcattcgcttag cactggcaca 2640  
 gatccaagta caccacagaa cattctacag attaaagatt tgaatttccc ctcaaggtcg 2700  
 tcgtctcgca tatccagcc ggagctgcac tacgccagcc tagatcttcc ccattgcagt 2760  
 ggccaaaatc cagctaaata cctgaagaga ggatcacgca aatcgccgcc ggtgtccgca 2820  
 tgcccggagg atggaaatac ctatgcgaaa atcgactttg accaatccga ctccctttcc 2880  
 tcctcatcga acatatttaa tacgtaa 2907

<210> 2  
 <211> 2907  
 <212> DNA  
 <213> *Drosophila melanogaster*

<220>  
 <221> CDS  
 <222> (1)...(2907)

<400> 2  
 atg gca tca ata tcg gat gac ggc atg gcg ctg agt ggc tac ctc aag 48  
 Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys  
 1 5 10 15

aag ctg aag acc atg aag aag aag ttc ttt gtg ctg tac gag gag acg 96  
 Lys Leu Lys Thr Met Lys Lys Phe Phe Val Leu Tyr Glu Glu Thr  
 20 25 30

agc act tcg gca gcc cgg ctg gag tac tac gat acc gaa aag aag ttc 144  
 Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe  
 35 40 45

ctg caa aga gcc gag cca aaa agg gtt ata tat ctg aag aat tgc ttc 192  
 Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe

50	55	60	
aac atc aat cgc cgt ttg gac acc aag cat aga ttt gtc att gtg ctc 240			
Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu			
65	70	75	80
tcc tcc aga gac ggt gga ttc ggc atc gtt ctc gag aac gaa aat gat 288			
Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp			
85	90	95	
tta cgc aaa tgg ttg gac aaa cta cta gtt cta caa agg aac ata gcc 336			
Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala			
100	105	110	
aat tcg aat gga aca gcg cac tca cct tat gac cac gtt tgg caa gtt 384			
Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val			
115	120	125	
gtc att caa aag aag ggt att tcg gag aaa gtt gga atc acc gga acc 432			
Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr			
130	135	140	
tac cac tgt tgc ctt act tca aaa tcc ctg aca ttc gtg tgc att gga 480			
Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly			
145	150	155	160
ccg gag aag acg ccc aat ggc gag gat cgc gtt gcg agc att gaa ata 528			
Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile			
165	170	175	
ctt ttg acc acg atc agg cga tgc ggt cat gca tcc cca caa tgt ata 576			
Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile			
180	185	190	
ttc tac gtg gaa ctt ggc cgc caa agt gtc ttg gga tct ggt gat ctg 624			
Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu			
195	200	205	
tgg atg gag acg gat aac gca gct att gct act aat atg cac aac acg 672			
Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr			
210	215	220	
ata ctg agc gct atg tca gcc aaa aca gag tcg aac acg aat tta ata 720			
Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile			
225	230	235	240
aac gtt tat cag aat aga cct gac tta agt cac gag ccc atg aga aag 768			
Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys			

245	250	255	
cga tcg tcg tct gca aac gaa gca tcg aag ccg ata aac gta aat gtc 816			
Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val			
260	265	270	
ata caa aat agt caa aac tct ctc gaa ttg cgc agc tgc agt tcg ccc 864			
Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro			
275	280	285	
cat aac tat ggt ttc ggc aga gag aga tgc gat agc tta cca acc aga 912			
His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg			
290	295	300	
aat gga acc cta agc gag tcc agc aat caa acg tac ttt ggt tcc aac 960			
Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn			
305	310	315	320
cat gga ctg cga tcc aat act ata tct ggc atc cgt ccg cac tca acc 1008			
His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr			
325	330	335	
aac aag cat agt aat agt cca acg ttc acc atg cca tta aga tgc tca 1056			
Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser			
340	345	350	
gaa tcc gaa gag tca tca att agt gtc gat gaa tcc gac gac aac ggc 1104			
Glu Ser Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly			
355	360	365	
agt ttt agc cac tac aga tta aac acg ccg tca tct gag acg gca att 1152			
Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile			
370	375	380	
cct gag gaa aac att gat gac ttt gcc agt gcg gaa tta ttt agc aaa 1200			
Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys			
385	390	395	400
gtc acc gaa caa aat gta agt gac gaa aac tac ata ccg atg aat cca 1248			
Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro			
405	410	415	
gtc aat cct acc gat gct atc cat gaa aag gag aag gct gat atg cag 1296			
Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln			
420	425	430	
aga ttg gaa gat gct tcg ctg cat ttc aac ttt ccg gag cac gcg tcg 1344			
Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser			

435	440	445	
gaa aag ctt gct aag gat ttt gat ctg gac tct gat aac caa tgc tgt			1392
Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys			
450	455	460	
cgt ccc att cgc gcc tat tcg ata ggc aac aag gtt gag cat tta aag			1440
Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys			
465	470	475	480
ttt aat aag cgc ctg gga cac ttg aat gat acg gga cag aat ccg aat			1488
Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn			
485	490	495	
cgc gtg cga gcc tac tcg gtt ggc tcc aaa tcg aag ata ccg cgc tgc			1536
Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys			
500	505	510	
gac ctg cag cga gtg gtc ctc gtg gag gac aat aaa cat gag ttc aca			1584
Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr			
515	520	525	
gcg aat agg agt cag agt agc att acc aag gaa gga acc agc tat ggc			1632
Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly			
530	535	540	
agc agt gcc aat cga caa aag aag tcc aca agt gct cca ctc ctc agt			1680
Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser			
545	550	555	560
ctg aag aac cag ata aac tcc gac cga atg agt gac tta atg gaa att			1728
Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile			
565	570	575	
gat ttt tca caa gca acc aat ttg gaa aag cag aag ttc atc aag aat			1776
Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn			
580	585	590	
aat gaa att ccg aaa tac att gaa aac gtg ttc cca aaa gcc ccg cga			1824
Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg			
595	600	605	
acg gat agc tcc agc cta act ctg cac gcc aca agt caa aag gac att			1872
Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile			
610	615	620	
ttc aat ggc acc aaa cta aat aac act gcg atc aca tcc gag gat ggt			1920
Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly			

625	630	635	640
tac ctc gag atg aag cca gtc ggt aat gga tac act ccc agt tcg aat			
Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn			
645	650	655	
tgc ctg cca atg aaa gtg gag aaa ctc aag cta tcc gac tat cag aca			
Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr			
660	665	670	
gca ccg cca ctc acc gca aca gcc gca cca gtg cac gat tta aac aaa			
Ala Pro Pro Leu Thr Ala Ala Pro Val His Asp Leu Asn Lys			
675	680	685	
att agc aca tac aat ata tcc gct gag aaa tgg aga gaa cag ccc agc			
Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser			
690	695	700	
aga agc gag gaa aag aag tcg aac tcg cca ttg aat gac aac acc ttt			
Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe			
705	710	715	720
agc tcg aaa ccc aca aat gtc gag agt aca agc aaa agc cat gat gtt			
Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val			
725	730	735	
cat tca gca aat caa att gat tgc gag aaa gtg tgc gcg cag agc agc			
His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser			
740	745	750	
gat aag cta aat aat cat ctg gcc gac aag att gtc gag aac aac aat			
Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn			
755	760	765	
ttg gat ata ggc ggg cat gag gaa aag aag ttg gtt cat tcg ata agc			
Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser			
770	775	780	
agc gaa gac tac aca caa atc aag gac aaa tcg aat gat ttc aca aaa			
Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys			
785	790	795	800
ttt aac gaa gcc ggc tac aaa att ctg caa att aaa agc gac agc tca			
Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser			
805	810	815	
ctc atc tca tcg aag cta tac caa aag ggt ata cac aag gat aac ttg			
Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu			

820

825

830

gag cgt tcg cag aga ctt aca gag agt gtg aat acg att ccc gat aat 2544  
 Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn

835

840

845

gcc acc gcc acc gcg gtg agc agc agc tca ctc acc aaa ttc aat ata 2592  
 Ala Thr Ala Thr Ala Val Ser Ser Ser Leu Thr Lys Phe Asn Ile  
 850 855 860

aat tca gca aag cca gcc gcc gat tcg cgt agc act ggc aca 2640  
 Asn Ser Ala Lys Pro Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr  
 865 870 875 880

gat cca agt aca cca cag aac att cta cag att aaa gat ttg aat ttc 2688  
 Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe  
 885 890 895

ccc tca agg tcg tcg tct cgc ata tcc cag ccg gag ctg cac tac gcc 2736  
 Pro Ser Arg Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala  
 900 905 910

agc cta gat ctt ccc cat tgc agt ggc caa aat cca gct aaa tac ctg 2784  
 Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu  
 915 920 925

aag aga gga tca cgc gaa tcg ccg ccg gtg tcc gca tgc ccg gag gat 2832  
 Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp  
 930 935 940

ggg aat acc tat gcg aaa atc gac ttt gac caa tcc gac tcc tct tcc 2880  
 Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser  
 945 950 955 960

tcc tca tcg aac ata ttt aat acg taa 2907  
 Ser Ser Ser Asn Ile Phe Asn Thr  
 965

&lt;210&gt; 3

&lt;211&gt; 969

&lt;212&gt; PRT

<213> *Drosophila melanogaster*

&lt;400&gt; 3

Met Ala Ser Ile Ser Asp Asp Gly Met Ala Leu Ser Gly Tyr Leu Lys

1

5

10

15

Lys	Leu	Lys	Thr	Met	Lys	Lys	Phe	Phe	Val	Leu	Tyr	Glu	Glu	Thr
20							25					30		
Ser Thr Ser Ala Ala Arg Leu Glu Tyr Tyr Asp Thr Glu Lys Lys Phe														
35					40				45					
Leu Gln Arg Ala Glu Pro Lys Arg Val Ile Tyr Leu Lys Asn Cys Phe														
50				55			60							
Asn Ile Asn Arg Arg Leu Asp Thr Lys His Arg Phe Val Ile Val Leu														
65			70		75		80							
Ser Ser Arg Asp Gly Gly Phe Gly Ile Val Leu Glu Asn Glu Asn Asp														
85			90		95									
Leu Arg Lys Trp Leu Asp Lys Leu Leu Val Leu Gln Arg Asn Ile Ala														
100			105		110									
Asn Ser Asn Gly Thr Ala His Ser Pro Tyr Asp His Val Trp Gln Val														
115			120		125									
Val Ile Gln Lys Lys Gly Ile Ser Glu Lys Val Gly Ile Thr Gly Thr														
130			135		140									
Tyr His Cys Cys Leu Thr Ser Lys Ser Leu Thr Phe Val Cys Ile Gly														
145			150		155		160							
Pro Glu Lys Thr Pro Asn Gly Glu Asp Arg Val Ala Ser Ile Glu Ile														
165			170		175									
Leu Leu Thr Thr Ile Arg Arg Cys Gly His Ala Ser Pro Gln Cys Ile														
180			185		190									
Phe Tyr Val Glu Leu Gly Arg Gln Ser Val Leu Gly Ser Gly Asp Leu														
195			200		205									
Trp Met Glu Thr Asp Asn Ala Ala Ile Ala Thr Asn Met His Asn Thr														
210			215		220									
Ile Leu Ser Ala Met Ser Ala Lys Thr Glu Ser Asn Thr Asn Leu Ile														
225			230		235		240							
Asn Val Tyr Gln Asn Arg Pro Asp Leu Ser His Glu Pro Met Arg Lys														
245			250		255									
Arg Ser Ser Ser Ala Asn Glu Ala Ser Lys Pro Ile Asn Val Asn Val														
260			265		270									

Ile Gln Asn Ser Gln Asn Ser Leu Glu Leu Arg Ser Cys Ser Ser Pro

275

280

285

His Asn Tyr Gly Phe Gly Arg Glu Arg Cys Asp Ser Leu Pro Thr Arg

290

295

300

Asn Gly Thr Leu Ser Glu Ser Ser Asn Gln Thr Tyr Phe Gly Ser Asn

305

310

315

320

His Gly Leu Arg Ser Asn Thr Ile Ser Gly Ile Arg Pro His Ser Thr

325

330

335

Asn Lys His Ser Asn Ser Pro Thr Phe Thr Met Pro Leu Arg Cys Ser

340

345

350

Glu Ser Glu Glu Ser Ser Ile Ser Val Asp Glu Ser Asp Asp Asn Gly

355

360

365

Ser Phe Ser His Tyr Arg Leu Asn Thr Arg Ser Ser Glu Thr Ala Ile

370

375

380

Pro Glu Glu Asn Ile Asp Asp Phe Ala Ser Ala Glu Leu Phe Ser Lys

385

390

395

400

Val Thr Glu Gln Asn Val Ser Asp Glu Asn Tyr Ile Pro Met Asn Pro

405

410

415

Val Asn Pro Thr Asp Ala Ile His Glu Lys Glu Lys Ala Asp Met Gln

420

425

430

Arg Leu Glu Asp Ala Ser Leu His Phe Asn Phe Pro Glu His Ala Ser

435

440

445

Glu Lys Leu Ala Lys Asp Phe Asp Leu Asp Ser Asp Asn Gln Cys Cys

450

455

460

Arg Pro Ile Arg Ala Tyr Ser Ile Gly Asn Lys Val Glu His Leu Lys

465

470

475

480

Phe Asn Lys Arg Leu Gly His Leu Asn Asp Thr Gly Gln Asn Pro Asn

485

490

495

Arg Val Arg Ala Tyr Ser Val Gly Ser Lys Ser Lys Ile Pro Arg Cys

500

505

510

Asp Leu Gln Arg Val Val Leu Val Glu Asp Asn Lys His Glu Phe Thr

515

520

525

Ala Asn Arg Ser Gln Ser Ser Ile Thr Lys Glu Gly Thr Ser Tyr Gly  
530 535 540

Ser Ser Ala Asn Arg Gln Lys Lys Ser Thr Ser Ala Pro Leu Leu Ser  
545 550 555 560

Leu Lys Asn Gln Ile Asn Ser Asp Arg Met Ser Asp Leu Met Glu Ile  
565 570 575

Asp Phe Ser Gln Ala Thr Asn Leu Glu Lys Gln Lys Phe Ile Lys Asn  
580 585 590

Asn Glu Ile Pro Lys Tyr Ile Glu Asn Val Phe Pro Lys Ala Pro Arg  
595 600 605

Thr Asp Ser Ser Ser Leu Thr Leu His Ala Thr Ser Gln Lys Asp Ile  
610 615 620

Phe Asn Gly Thr Lys Leu Asn Asn Thr Ala Ile Thr Ser Glu Asp Gly  
625 630 635 640

Tyr Leu Glu Met Lys Pro Val Gly Asn Gly Tyr Thr Pro Ser Ser Asn  
645 650 655

Cys Leu Pro Met Lys Val Glu Lys Leu Lys Leu Ser Asp Tyr Gln Thr  
660 665 670

Ala Pro Pro Leu Thr Ala Thr Ala Ala Pro Val His Asp Leu Asn Lys  
675 680 685

Ile Ser Thr Tyr Asn Ile Ser Ala Glu Lys Trp Arg Glu Gln Pro Ser  
690 695 700

Arg Ser Glu Glu Lys Lys Ser Asn Ser Pro Leu Asn Asp Asn Thr Phe  
705 710 715 720

Ser Ser Lys Pro Thr Asn Val Glu Ser Thr Ser Lys Ser His Asp Val  
725 730 735

His Ser Ala Asn Gln Ile Asp Cys Glu Lys Val Cys Ala Gln Ser Ser  
740 745 750

Asp Lys Leu Asn Asn His Leu Ala Asp Lys Ile Val Glu Asn Asn Asn  
755 760 765

Leu Asp Ile Gly Gly His Glu Glu Lys Lys Leu Val His Ser Ile Ser  
770 775 780

Ser Glu Asp Tyr Thr Gln Ile Lys Asp Lys Ser Asn Asp Phe Thr Lys  
 785 790 795 800

Phe Asn Glu Ala Gly Tyr Lys Ile Leu Gln Ile Lys Ser Asp Ser Ser  
 805 810 815

Leu Ile Ser Ser Lys Leu Tyr Gln Lys Gly Ile His Lys Asp Asn Leu  
 820 825 830

Glu Arg Ser Gln Arg Leu Thr Glu Ser Val Asn Thr Ile Pro Asp Asn  
 835 840 845

Ala Thr Ala Thr Ala Val Ser Ser Ser Leu Thr Lys Phe Asn Ile  
 850 855 860

Asn Ser Ala Lys Pro Ala Ala Ala Asp Ser Arg Ser Thr Gly Thr  
 865 870 875 880

Asp Pro Ser Thr Pro Gln Asn Ile Leu Gln Ile Lys Asp Leu Asn Phe  
 885 890 895

Pro Ser Arg Ser Ser Arg Ile Ser Gln Pro Glu Leu His Tyr Ala  
 900 905 910

Ser Leu Asp Leu Pro His Cys Ser Gly Gln Asn Pro Ala Lys Tyr Leu  
 915 920 925

Lys Arg Gly Ser Arg Glu Ser Pro Pro Val Ser Ala Cys Pro Glu Asp  
 930 935 940

Gly Asn Thr Tyr Ala Lys Ile Asp Phe Asp Gln Ser Asp Ser Ser Ser  
 945 950 955 960

Ser Ser Ser Asn Ile Phe Asn Thr  
 965

<210> 4

<211> 5210

<212> DNA

<213> *Drosophila melanogaster*

<400> 4

agaacgactt tttcctcctt agtcagtcac aagaaaacta aagcttacca acaatacggc 60

gtgtattgtt aaatttattac aacaaataaa atattcaaat tgtatttaaa aatatagtaa 120

ccattaaaaa ataaaaatcaa tatgcgaaac tttgtaattt cttactcatc cttgttttt 180

gagcccgctt tcttaagtta aatcgtaaaa ataccagttt aatcattca ttgcctgat 240  
ttcaggagct aattacattt taatcttgt ataaattcat aaaattaaaa tggaaatgtt 300  
taaccacata aaatatttggt gtatataaaag tcgatacata cttttaaaat tttgtttcat 360  
acaagaatat ggaaagtaga taattttagtt accgattaaa acatttctaa aatacaaaaa 420  
atttaaaatg atgattaaat aaaaaactgt tatactaaat ttaaacgaaa caaacggta 480  
ttcgataact caattagttat cgaataagcc ggcgtgtaaa tcgggttggc aactctcacc 540  
ggttagaga tcgggatggc aacttcgtat tgttattcct atgctgcgt aacgataaca 600  
gcaaagtgtc atcgcgaata aatgtgggtt tgataataaa gaattgcgtt ggtgaacaat 660  
aataatacaa atgctaaatg tatcgcgccg ataactagta aacactgatt tcgccccat 720  
cgggcatacg ggcagctaga cgtcttaggt aacacatttc ccagccacat tggcggtgag 780  
gtattatttc ccataccat gtgcgtttgt aaatgataacc accagagtgt gccatatgt 840  
tcgttgggg tacatacatg cctacggggaaaataactc gcagatacat atgtatgtaa 900  
gatgtatttag aattccacag atatatgtac atataaatat atatatatat ttatgtatgct 960  
catctataaa acaaaatatg tacaaacata cgcgcgcacg tacttatgtt tgtacatata 1020  
catatataca tatatgtata ataaaatgag catctagctg cggttatctt aatgcaatgc 1080  
gcagaaacct gaaaacgaaa taaacaatct ttacagcgcc agcacagtga gccaaattatg 1140  
aattcacaat tccacatcca attccgattc cgaattccat cgcttacat cctaattcga 1200  
atacgctcgcc cgcgtaaagc tgcactcgaa tattgacata aacgacgtaa ttgcgtgttt 1260  
tgattgcgt ttccgatgct cgatgttgac agacggcaag gatTTTTT gcccggac 1320  
attgcgaatg ctttcgcgt gtttgcgtg tgaaaagcga tttgttggc cggcagttgg 1380  
aaatgttttg tgctgtttat gcttagaaaa gcaaatgtat tgcacaaaac tcgtgtttcc 1440  
tacattagta aagcctataa ctttaggtata tgtttctaaa ttacaatgca aaaaataaaaa 1500  
aacattatac atgtgttcgt tctttaattt gaaaacagaa aagtgaaagc cttgcaaatc 1560  
aaatatgtgt ccatacgcc tactaataat ataaacacgt cgcctccag gaactaagat 1620

tgaaaatcat ggcataata tcggatgacg gcatggcgct gagtggctac ctcaagaagc 1680  
tgaagaccat gaagaagaag ttctttgtgc tgtacgagga gacgagcact tcggcagccc 1740  
ggctggagta ctacgatacc gaaaagaagt tcctgcaaag agccgagcca aaaagggtta 1800  
tctatctgaa gaattgcttc aacatcaatc gccgttgga caccaagcat agatttgc 1860  
tttgctctc ctccagagac ggtggattcg gcatcgttct cgagaacgaa aatgatttac 1920  
gcaaatgggtt ggacaaacta ctatgttac aaaggaacat agccaattcg aatgaaacag 1980  
cgcaactcacc ttatggtatg ccaaataaac tataactacc agttgtatg aaacctaaac 2040  
acttcatttc actttgcaga ccacgttg caagttgtca ttcaaaagaa gggtatttcg 2100  
gagaaagttt gaatcaccgg aacctaccac tggccctta cttcaaaatc cctgacattc 2160  
gtgtgcattt gaccggagaa gacgccaat ggcgaggatc gcgttgcgag cattgaaata 2220  
cttttgcacca cgatcaggcg gttagttgtt gccagcaaaa ctgcaaggaa ttgtaaaata 2280  
atccggactt aatttcagat gcggtcatgc atccccacaa tgtatattct acgtggaact 2340  
tggccgccaa agtgttctgg gatctggta tctgtggatg gagacggata acgcagctat 2400  
tgctactaat atgcacaaca cgatactgag gtatttagct ctcattacaa ctaatccaag 2460  
atttcatgat catcctacaa aacgacatag atagtttaag atatctccca gttaacttta 2520  
ataattctgt gggtttttc tttcagcgct atgtcagcca aaacagagtc gaacacgaat 2580  
ttaataaacg tttatcagaa cagacctgac ttaagtcacg agcccatgag aaagcgatcg 2640  
tcgtctgcaa acgaagcatc gaagccgata aacgtaaatg tcatacaaaa tagtcaaaac 2700  
tctctcgaat tgccgagctg cagttcgccc cataactatg gtaaaatactt caaatgtatg 2760  
tttaaacgca aaattaatca aacgcaatcg tttcaggttt cggcagagag agatgcgata 2820  
gcttaccaac cagaaatgga accctaagcg agtccagcaa tcaaacgtac tttggttcca 2880  
accatggact gcgatccaaat actatatctg gcatccgtcc gcactcaacc aacaagcata 2940  
gtaatagtcc aacgttcacc atgccattaa gatgctcaga atccgaagag tcataatta 3000  
gtgtcgatga atccgacgac aacggcagtt ttagccacta cagattaaag tgcgttgcta 3060

tcaaataata attatttaat aataatcacc atttcaattt ctgcacgct gtcatctgag 3120  
acggcaattc ctgaggaaaa cattgatgac tttgccagtg cgaaattatt tagcaaagtc 3180  
accgaacaaa atggtaagcc aaacacaaaa acaattttt aacatgaaaa gtagctaattc 3240  
aattggcttt gtttaactgc agtaagtgac gaaaactaca taccgatgaa tccagtcatt 3300  
cctaccgatg ctatccatga aaaggagaag gctgatgc agagattgga agatgcttcg 3360  
ctgcatttca actttccgga gcacgcgtcg gaaaagcttg ctaaggattt tgatctggac 3420  
tctgataacc agtgagtaca catttcgctt caactgtgcc acgtaatgca atcaatcaca 3480  
tcttggttaca gatgctgtcg tcccattcgc gcctattcga taggcaacaa ggttgagcat 3540  
ttaaagttta ataaggcct gggacacttg aatgatacgg gacagaatcc gaatcgctg 3600  
cgagcctact cggttggctc caaatcgaag ataccgcgtc gcgacctgca gcgagtggtc 3660  
ctcgtggagg acaataaaca tgagttcaca gcgaatagga gtcagagtag cattaccaag 3720  
gaaggaacca gctatggcag cagtgc当地 cgacaaaaga agtccacaag tgctccactc 3780  
ctcagtctga agaaccagat aaactccgac cgaatgagtg acttaatgga aattgatttt 3840  
tcacaagcaa ccaatttggaa aaagcagaag ttcatcaaga ataatgaaat tccgaaatac 3900  
attgaaaacg tggtccaaaa agccccgcga acggatagct ccagcctaac tctgcacgcc 3960  
acaagtcaaa aggacattt caatggcacc aaactaaata acactgcgt cacatccgag 4020  
gatggttacc tcgagatgaa gccagtcggt aatggataca ctcccagttc gaattgcctg 4080  
ccaatgaaag tggagaggct caagctatcc gactatcaga cagcaccgcc aatcaccgca 4140  
acagccgcac cagtgcacga tttaaacaata attagcacat acaatatac cgctgagaaa 4200  
tgagagaaac agccccagcag aagcgaggaa aagaagtcga actcgccatt gaatgacaac 4260  
acctttggct tgaaacccac aaatgtcgag agtacaagca aaagccatga tgttcattca 4320  
gcaaataaaa ttgattccga gaaagtgtgc gcgcagagca gcgataagct aaataatctg 4380  
gccgacaaga ttgtcgagaa caacaattt gatataggcg ggcattgagga aaagaagttg 4440  
gttcattcga taagcagcga agactacaca caaatcaagg acaaatacgaa tgatttcaca 4500

aaatttaacg aagccggcta caaaattctg caaattaaaa gcgacagctc actcatctca 4560  
tcgaagctat accaaaaggg tatacacaag gataacttgg agcgttcgca gagacttacg 4620  
gagagtgtga atacgattcc cgataatgcc accgcccacccg cggtgagcag cagctcactc 4680  
accaaattca atataaattc agcaaagcca gcccgcgcg ccgattcgcg tagcactggc 4740  
acagatccaa gtacaccaca gaacattcta cagattaaag atttgaattt cccctcaagg 4800  
tcgtcgtctc gcatatccca gccggagctg cactacgcca gcctagatct tccccattgc 4860  
agtggccaaa atccagctaa atacctgaag agaggatcac gcgaatcgcc gccggtgtcc 4920  
gcatgcccgg aggatggaa tacctatgcg aaaatcgact ttgaccaatc cgactcctct 4980  
tcctcctcat cgaacatatt taatacgtaa agtttgaaa tttatgaccc tattctat 5040  
atatgatttg tttaatattt tacattttt gtaaatattt tctgacaagc aaagcttaca 5100  
attttggatg ctaataaata aatttttattt aaattataat gatccctttg gactttttt 5160  
tttttggac taagaaatca ctactaaaga agggctttc gagggttaaa 5210